Diabetes & Metabolism Journal

Original Articles

Metabolic Risk/Epidemiology
Association of Uterine Leiomyoma with Type 2 Diabetes Mellitus in Young Women: A Population-Based Cohort Study: Ji-Hee Sung, Kyung-Soo Kim, Kyungdo Han, Cheol-Young Park; Received December 8, 2023 Accepted June 17, 2024 Published online August 19, 2024; DOI: https://doi.org/10.4093/dmj.2023.0444 [Epub ahead of print]

540 View
44 Download

Abstract PDF Supplementary Material PubReader ePub: Background
We investigated the association between uterine leiomyoma (UL) and incident type 2 diabetes mellitus (T2DM) in young women.
Methods
A nationwide population-based cohort study of 2,541,550 women aged between 20 and 40 years was performed using the National Health Information Database. Cox proportional hazards models were used to analyze the risk of incident T2DM according to the presence of UL and myomectomy.
Results
The mean age was 29.70 years, and mean body mass index was 21.31 kg/m2. Among 2,541,550 participants, 18,375 (0.72%) women had UL. During a median 7.45 years of follow-up, 23,829 women (0.94%) were diagnosed with T2DM. The incidence of T2DM in women with UL (1.805/1,000 person-years) was higher than in those without UL (1.289/1,000 person-years). Compared with women without UL, women with UL had a higher risk of incident T2DM (hazard ratio, 1.216; 95% confidence interval [CI], 1.071 to 1.382). Women with UL who did not undergo myomectomy had a 1.505 times (95% CI, 1.297 to 1.748) higher risk for incident T2DM than women without UL. However, women with UL who underwent myomectomy did not have increased risk for incident T2DM.
Conclusion
Young women with UL were associated with a high risk of incident T2DM. In addition, myomectomy seemed to attenuate the risk for incident T2DM in young women with UL.

Drug/Regimen
Safety and Effectiveness of Dulaglutide in the Treatment of Type 2 Diabetes Mellitus: A Korean Real-World Post-Marketing Study: Jeonghee Han, Woo Je Lee, Kyu Yeon Hur, Jae Hyoung Cho, Byung Wan Lee, Cheol-Young Park; Diabetes Metab J. 2024;48(3):418-428. Published online February 2, 2024; DOI: https://doi.org/10.4093/dmj.2023.0030

2,341 View
287 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
To investigate the real-world safety and effectiveness of dulaglutide in Korean adults with type 2 diabetes mellitus (T2DM).
Methods
This was a real-world, prospective, non-interventional post-marketing safety study conducted from May 26, 2015 to May 25, 2021 at 85 Korean healthcare centers using electronic case data. Data on patients using dulaglutide 0.75 mg/0.5 mL or the dulaglutide 1.5 mg/0.5 mL single-use pens were collected and pooled. The primary objective was to report the frequency and proportion of adverse and serious adverse events that occurred. The secondary objective was to monitor the effectiveness of dulaglutide at 12 and 24 weeks by evaluating changes in glycosylated hemoglobin (HbA1c ), fasting plasma glucose, and body weight.
Results
Data were collected from 3,067 subjects, and 3,022 subjects who received ≥1 dose (of any strength) of dulaglutide were included in the safety analysis set (53% female, mean age 56 years; diabetes duration 11.2 years, mean HbA1c 8.8%). The number of adverse events reported was 819; of these, 68 (8.3%) were serious adverse events. One death was reported. Adverse events were mostly mild in severity; 60.81% of adverse events were considered related to dulaglutide. This study was completed by 72.73% (2,198/3,022) of subjects. At 12/24 weeks there were significant (P<0.0001) reductions from baseline in least-squares mean HbA1c (0.96%/0.95%), fasting blood glucose (26.24/24.43 mg/dL), and body weight (0.75/1.21 kg).
Conclusion
Dulaglutide was generally well tolerated and effective in real-world Korean individuals with T2DM. The results from this study contribute to the body of evidence for dulaglutide use in this population.

Citations

Citations to this article as recorded by

One-year Efficacy and Safety of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Study of Asian Patients
Myung Jin Kim, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee
Clinical Therapeutics.2024; 46(9): 683. CrossRef

Drug Regimen
Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension: Jun Sung Moon, Il Rae Park, Hae Jin Kim, Choon Hee Chung, Kyu Chang Won, Kyung Ah Han, Cheol-Young Park, Jong Chul Won, Dong Jun Kim, Gwan Pyo Koh, Eun Sook Kim, Jae Myung Yu, Eun-Gyoung Hong, Chang Beom Lee, Kun-Ho Yoon; Diabetes Metab J. 2023;47(6):808-817. Published online September 26, 2023; DOI: https://doi.org/10.4093/dmj.2022.0387

4,039 View
345 Download
1 Web of Science
1 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study investigates the long-term efficacy and safety of evogliptin add-on therapy in patients with inadequately controlled type 2 diabetes mellitus (T2DM) previously received dapagliflozin and metformin (DAPA/MET) combination.
Methods
In this multicenter randomized placebo-controlled phase 3 trial, patients with glycosylated hemoglobin (HbA1c) levels 7.0% to 10.5% (n=283) previously used DAPA 10 mg plus MET (≥1,000 mg) were randomly assigned to the evogliptin 5 mg once daily or placebo group (1:1). The primary endpoint was the difference in the HbA1c level from baseline at week 24, and exploratory endpoints included the efficacy and safety of evogliptin over 52 weeks (trial registration: ClinicalTrials.gov NCT04170998).
Results
Evogliptin add-on to DAPA/MET therapy was superior in HbA1c reduction compared to placebo at weeks 24 and 52 (least square [LS] mean difference, –0.65% and –0.55%; 95% confidence interval [CI], –0.79 to –0.51 and –0.71 to –0.39; P<0.0001). The proportion of patients achieving HbA1c <7% was higher in the triple combination group at week 52 (32.14% vs. 8.51% in placebo; odds ratio, 5.62; P<0.0001). Evogliptin significantly reduced the fasting glucose levels and mean daily glucose levels with improvement in homeostatic model assessment of β-cell function (LS mean difference, 9.04; 95% CI, 1.86 to 16.21; P=0.0138). Adverse events were similar between the groups, and no serious adverse drug reactions were reported in the evogliptin group.
Conclusion
Long-term triple combination with evogliptin added to DAPA/MET showed superior HbA1c reduction and glycemic control compared to placebo at 52 weeks and was well tolerated.

Citations

Citations to this article as recorded by

Efficacy and safety of dapagliflozin add‐on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled study
In‐Kyung Jeong, Kyung Mook Choi, Kyung Ah Han, Kyoung‐Ah Kim, In Joo Kim, Seung Jin Han, Won Young Lee, Soon Jib Yoo
Diabetes, Obesity and Metabolism.2024;[Epub] CrossRef

Guideline/Fact Sheet
Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017: Eugene Han, Kyung-Do Han, Yong-ho Lee, Kyung-Soo Kim, Sangmo Hong, Jung Hwan Park, Cheol-Young Park, on Behalf of Fatty Liver Research Group of the Korean Diabetes Association; Diabetes Metab J. 2023;47(3):347-355. Published online March 29, 2023; DOI: https://doi.org/10.4093/dmj.2022.0444

4,871 View
237 Download
12 Web of Science
14 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
This study investigated the changes of fatty liver disease prevalence in general Korean population.
Methods
This study analyzed data from the Korean National Health Insurance Service from 2009 to 2017 that included individuals aged 20 years or older who had undergone a medical health examination. Fatty liver disease was assessed using the fatty liver index (FLI). The disease severity was defined by FLI cutoff, ≥30 as moderate, and ≥60 as severe fatty liver disease.
Results
The prevalence of Korean adults aged 20 years or over with fatty liver disease (FLI ≥60) increased from 13.3% in 2009 to 15.5% in 2017 (P for trend <0.001). The increase in fatty liver disease prevalence was prominent in men (from 20.5% to 24.2%) and the young age (20 to 39 years) group (from 12.8% to 16.4%) (P for interaction <0.001). The prevalence of fatty liver disease was the highest in type 2 diabetes mellitus (T2DM, 29.6%) population compared to that of prediabetes or normoglycemia (10.0% and 21.8%) in 2017. The prevalence of fatty liver disease had statistically increased in individuals with T2DM and prediabetes (P for trend <0.001). Its prevalence increased more steeply in the young-aged population with T2DM, from 42.2% in 2009 to 60.1% in 2017. When applying a lower FLI cutoff (≥30) similar results were observed.
Conclusion
The prevalence of fatty liver disease in the Korean population has increased. Individuals who are young, male, and have T2DM are vulnerable to fatty liver disease.

Citations

Citations to this article as recorded by

Longitudinal changes in fatty liver index are associated with risk of hepatocellular carcinoma: A nationwide cohort study in Korea
Min Gu Kang, Chang Hun Lee, Chen Shen, Jong Seung Kim, Ji Hyun Park
Journal of Hepatology.2024; 80(5): e216. CrossRef
Repeated detection of non‐alcoholic fatty liver disease increases the incidence risk of type 2 diabetes in young adults
Jin Hwa Kim, Young Sang Lyu, Mee Kyoung Kim, Sang Yong Kim, Ki‐Hyun Baek, Ki‐Ho Song, Kyungdo Han, Hyuk‐Sang Kwon
Diabetes, Obesity and Metabolism.2024; 26(1): 180. CrossRef
Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim
Metabolism.2024; 152: 155789. CrossRef
Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
BMJ.2024; : e076388. CrossRef
Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome
Scott L. Friedman
Diabetes & Metabolism Journal.2024; 48(2): 161. CrossRef
Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
Inha Jung, Dae-Jeong Koo, Won-Young Lee
Diabetes & Metabolism Journal.2024; 48(3): 327. CrossRef
Association between long working hours and metabolic dysfunction–associated steatotic liver disease: a nationwide population-based study in Korea
S.-U. Baek, J.-U. Won, Y.-M. Lee, J.-H. Yoon
Public Health.2024; 232: 188. CrossRef
Association between Dietary Quality and Non-Alcoholic Fatty Liver Disease in Korean Adults: A Nationwide, Population-Based Study Using the Korean Healthy Eating Index (2013–2021)
Seong-Uk Baek, Taeyeon Kim, Yu-Min Lee, Jong-Uk Won, Jin-Ha Yoon
Nutrients.2024; 16(10): 1516. CrossRef
Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study
Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon
American Journal of Gastroenterology.2024;[Epub] CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung
Cancers.2024; 16(18): 3161. CrossRef
Reply to G. Wang et al
Joo-Hyun Park, Jung Yong Hong, Kyungdo Han
Journal of Clinical Oncology.2023; 41(32): 5070. CrossRef
The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review
Teodora Biciusca, Sorina Ionelia Stan, Mara Amalia Balteanu, Ramona Cioboata, Alice Elena Ghenea, Suzana Danoiu, Ana-Maria Bumbea, Viorel Biciusca
Diagnostics.2023; 13(21): 3316. CrossRef
Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?
Eugene Han, Yong-ho Lee
Clinical and Molecular Hepatology.2023; 29(4): 980. CrossRef
Approach to Fatty Liver Disease in Patients with Type 2 Diabetes
Ji Cheol Bae
The Journal of Korean Diabetes.2023; 24(3): 107. CrossRef

Metabolic Risk/Epidemiology
Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study: Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park; Diabetes Metab J. 2023;47(2):220-231. Published online January 12, 2023; DOI: https://doi.org/10.4093/dmj.2021.0327

65,535 View
313 Download
13 Web of Science
12 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We investigated whether metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with an elevated risk of all-cause and cardiovascular mortality using a large-scale health examination cohort.
Methods
A total of 394,835 subjects in the Kangbuk Samsung Health Study cohort were enrolled from 2002 to 2012. Participants were categorized by the presence of nonalcoholic fatty liver disease (NAFLD) and MAFLD as follows: normal subjects; patients with both NAFLD and MAFLD; patients with NAFLD only; and patients with MAFLD only. Cox proportional hazards models were used to analyze the risk of mortality.
Results
During a median 5.7 years of follow-up, 20.69% was patients with both NAFLD and MAFLD, 1.51% was patients with NAFLD only, and 4.29% was patients with MAFLD only. All-cause and cardiovascular death was higher in patients with MAFLD than those without MAFLD (P<0.001, respectively). In patients with MAFLD only, the hazard ratio (HR) of all-cause and cardiovascular death was 1.35 (95% confidence interval [CI], 1.13 to 1.60) and 1.90 (95% CI, 1.26 to 2.88) after adjusting for age, which lost its statistical significance by multivariable adjustments. Compared to patients with less than two components of metabolic dysfunction, patients with more than two components of metabolic dysfunction were a higher risk of cardiovascular death (HR, 2.05; 95% CI, 1.25 to 3.38) and only women with more than two components of metabolic dysfunction were a higher risk of all-cause death (HR, 1.44; 95% CI, 1.02 to 2.03).
Conclusion
MAFLD criteria could identify a high-risk group for all-cause and cardiovascular death.

Citations

Citations to this article as recorded by

Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim
Metabolism.2024; 152: 155789. CrossRef
Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
BMJ.2024; : e076388. CrossRef
Sex differences in mortality and liver‐related events in non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
Huimin Zhou, Haiyan Chen, Hanxiao Lu, Bo Wu, Shuo Zhang, Yuanlong Gu, Guangwen Zhou, Jie Xiang, Jun Yang
Liver International.2024; 44(7): 1600. CrossRef
Association between dietary carbohydrate to fiber ratio and metabolic dysfunction associated fatty liver disease in adults: evidence from the NHANES 2017–2020
Zhenmin Liu, Taiyong Fang
Journal of Health, Population and Nutrition.2024;[Epub] CrossRef
NAFLD and MAFLD independently increase the risk of major adverse cardiovascular events (MACE): a 20-year longitudinal follow-up study from regional Australia
Karl Vaz, William Kemp, Ammar Majeed, John Lubel, Dianna J. Magliano, Kristen M. Glenister, Lisa Bourke, David Simmons, Stuart K. Roberts
Hepatology International.2024; 18(4): 1135. CrossRef
Clinical outcomes of MAFLD versus NAFLD: A meta‐analysis of observational studies
Grazia Pennisi, Giuseppe Infantino, Ciro Celsa, Gabriele Di Maria, Marco Enea, Marco Vaccaro, Roberto Cannella, Carlo Ciccioli, Claudia La Mantia, Alessandro Mantovani, Francesco Mercurio, Herbert Tilg, Giovanni Targher, Vito Di Marco, Calogero Cammà, Sal
Liver International.2024;[Epub] CrossRef
Comparison of Outcomes Between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-alcoholic Fatty Liver Disease: A Meta-Analysis
Ghazala S Virk, Jaahnavi Vajje, Nausheen K Virk, Raam Mannam, Wajeeh Rehman, Naglaa G Ghobriel , Irfan-ud-din Mian, Muhammad Usama
Cureus.2023;[Epub] CrossRef
Trends in prevalence and all-cause mortality of metabolic dysfunction-associated fatty liver disease among adults in the past three decades: Results from the NHANES study
Zhi-Qin Xie, Hong-Xia Li, Bing-Kun Wang, Zhao-Ming Yang, Zi-Yu Zhang, Wen-Liang Tan, Wen-Xin Li, Qing-Bin Wang, Lei Yang, Hong-Kai Zhuang, Chen-Wei Tang, Chang-Zhen Shang, Ya-Jin Chen
European Journal of Internal Medicine.2023; 110: 62. CrossRef
Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
Han Na Jung, Chang Hee Jung
Diabetes & Metabolism Journal.2023; 47(2): 198. CrossRef
Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
Metabolism.2023; 145: 155612. CrossRef
Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes
Karl Vaz, Daniel Clayton-Chubb, Ammar Majeed, John Lubel, David Simmons, William Kemp, Stuart K. Roberts
Hepatology International.2023; 17(5): 1082. CrossRef
Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Soyeon Shin, Jaeyoung Kim, Ju Yeon Lee, Jun Kim, Chang-Myung Oh
Journal of Obesity & Metabolic Syndrome.2023; 32(4): 289. CrossRef

Drug/Regimen
A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus: Bo-Yeon Kim, Hyuk-Sang Kwon, Suk Kyeong Kim, Jung-Hyun Noh, Cheol-Young Park, Hyeong-Kyu Park, Kee-Ho Song, Jong Chul Won, Jae Myung Yu, Mi Young Lee, Jae Hyuk Lee, Soo Lim, Sung Wan Chun, In-Kyung Jeong, Choon Hee Chung, Seung Jin Han, Hee-Seok Kim, Ju-Young Min, Sungrae Kim; Diabetes Metab J. 2022;46(6):855-865. Published online March 8, 2022; DOI: https://doi.org/10.4093/dmj.2021.0264

8,163 View
327 Download
6 Web of Science
7 Crossref

Abstract PDF PubReader ePub

Background
Thiazolidinediones (TZDs) have been associated with various safety concerns including weight gain, bladder cancer, and congestive heart failure (CHF). This study evaluated the efficacy and safety of lobeglitazone, a novel TZD in patients with type 2 diabetes mellitus (T2DM) in real practice.
Methods
In this non-interventional, multi-center, retrospective, and observational study conducted at 15 tertiary or secondary referral hospitals in Korea, a total of 2,228 patients with T2DM who received lobeglitazone 0.5 mg for more than 1 year were enrolled.
Results
Overall adverse events (AEs) occurred in 381 patients (17.10%) including edema in 1.97% (n=44). Cerebrovascular and cardiovascular diseases were identified in 0.81% (n=18) and 0.81% (n=18), respectively. One case of CHF was reported as an AE. Edema occurred in 1.97% (n=44) of patients. Hypoglycemia occurred in 2.47% (n=55) of patients. Fracture occurred in 1.17% (n=26) of all patients. Lobeglitazone significantly decreased HbA1c level, resulting in a mean treatment difference of -1.05%± 1.35% (P<0.001), and decreased total cholesterol, triglyceride, and low-density lipoprotein cholesterol. However, it increased high-density lipoprotein cholesterol, regardless of statin administration. The patients who received lobeglitazone 0.5 mg showed an apparent reduction in glycosylated hemoglobin (HbA1c) from baseline during the first 6 months of treatment. The HbA1c levels remained stable between months 6 and 42.
Conclusion
Lobeglitazone has long-term safety profile, good glycemic-lowering effect and long-term durability of glycemic control in real-world clinical settings.

Citations

Citations to this article as recorded by

Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis
Deep Dutta, Saptarshi Bhattacharya, Manoj Kumar, Priyankar K. Datta, Ritin Mohindra, Meha Sharma
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102697. CrossRef
Efficacy and safety of lobeglitazone, a new Thiazolidinedione, as compared to the standard of care in type 2 diabetes mellitus: A systematic review and meta-analysis
Shashank R. Joshi, Saibal Das, Suja Xaviar, Shambo Samrat Samajdar, Indranil Saha, Sougata Sarkar, Shatavisa Mukherjee, Santanu Kumar Tripathi, Jyotirmoy Pal, Nandini Chatterjee
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(1): 102703. CrossRef
Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal
Kalyan Kumar Gangopadhyay, Awadhesh Kumar Singh
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(4): 102747. CrossRef
Lobeglitazone

Reactions Weekly.2023; 1948(1): 262. CrossRef
Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim
Cardiovascular Diabetology.2023;[Epub] CrossRef
Lobeglitazone and Its Therapeutic Benefits: A Review
Balamurugan M, Sarumathy S, Robinson R
Cureus.2023;[Epub] CrossRef
Oldies but Goodies: Thiazolidinedione as an Insulin Sensitizer with Cardioprotection
Eun-Hee Cho
Diabetes & Metabolism Journal.2022; 46(6): 827. CrossRef

Metabolic Risk/Epidemiology
Current Status of Low-Density Lipoprotein Cholesterol Target Achievement in Patients with Type 2 Diabetes Mellitus in Korea Compared with Recent Guidelines: Soo Jin Yun, In-Kyung Jeong, Jin-Hye Cha, Juneyoung Lee, Ho Chan Cho, Sung Hee Choi, SungWan Chun, Hyun Jeong Jeon, Ho-Cheol Kang, Sang Soo Kim, Seung-Hyun Ko, Gwanpyo Koh, Su Kyoung Kwon, Jae Hyuk Lee, Min Kyong Moon, Junghyun Noh, Cheol-Young Park, Sungrae Kim; Diabetes Metab J. 2022;46(3):464-475. Published online March 3, 2022; DOI: https://doi.org/10.4093/dmj.2021.0088

8,176 View
379 Download
5 Web of Science
8 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
We evaluated the achievement of low-density lipoprotein cholesterol (LDL-C) targets in patients with type 2 diabetes mellitus (T2DM) according to up-to-date Korean Diabetes Association (KDA), European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS), and American Diabetes Association (ADA) guidelines.
Methods
This retrospective cohort study collected electronic medical record data from patients with T2DM (≥20 years) managed by endocrinologists from 15 hospitals in Korea (January to December 2019). Patients were categorized according to guidelines to assess LDL-C target achievement. KDA (2019): Very High-I (atherosclerotic cardiovascular disease [ASCVD]) <70 mg/dL; Very High-II (target organ damage [TOD], or cardiovascular risk factors [CVRFs]) <70 mg/dL; high (others) <100 mg/dL. ESC/EAS (2019): Very High-I (ASCVD): <55 mg/dL; Very High-II (TOD or ≥3-CVRF) <55 mg/dL; high (diabetes ≥10 years without TOD plus any CVRF) <70 mg/dL; moderate (diabetes <10 years without CVRF) <100 mg/dL. ADA (2019): Very High-I (ASCVD); Very High-II (age ≥40+ TOD, or any CVRF), for high intensity statin or statin combined with ezetimibe.
Results
Among 2,000 T2DM patients (mean age 62.6 years; male 55.9%; mean glycosylated hemoglobin 7.2%) ASCVD prevalence was 24.7%. Of 1,455 (72.8%) patients treated with statins, 73.9% received monotherapy. According to KDA guidelines, LDL-C target achievement rates were 55.2% in Very High-I and 34.9% in Very High-II patients. With ESC/EAS guidelines, target attainment rates were 26.6% in Very High-I, 15.7% in Very High-II, and 25.9% in high risk patients. Based on ADA guidelines, most patients (78.9%) were very-high risk; however, only 15.5% received high-intensity statin or combination therapy.
Conclusion
According to current dyslipidemia management guidelines, LDL-C goal achievement remains suboptimal in Korean patients with T2DM.

Citations

Citations to this article as recorded by

Risk factor control and cardiovascular events in patients with type 2 diabetes mellitus
Do Kyeong Song, Young Sun Hong, Yeon-Ah Sung, Hyejin Lee, Hidetaka Hamasaki
PLOS ONE.2024; 19(2): e0299035. CrossRef
Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial
Sang-Hyeon Ju, Joung Youl Lim, Minchul Song, Ji Min Kim, Yea Eun Kang, Hyon-Seung Yi, Kyong Hye Joung, Ju Hee Lee, Hyun Jin Kim, Bon Jeong Ku
Frontiers in Endocrinology.2024;[Epub] CrossRef
Monitoring Global Progress in Core Diabetes Control Metrics: Protocol for a Systematic Review of Prevalence (2015–2023)
John McCaffrey, Samira Barbara Jabakhanji, Roopa Mehta, Steven James, Maisoon Mairghani, Dominika Bhatia, Hazel Ní Chonchubhair, Killian Walsh, Barbara Clyne, Edward W. Gregg
HRB Open Research.2024; 7: 27. CrossRef
Real-world evidence evaluation of LDL-C in hospitalized patients: a population-based observational study in the timeframe 2021–2022
Umberto Capece, Chiara Iacomini, Teresa Mezza, Alfredo Cesario, Carlotta Masciocchi, Stefano Patarnello, Andrea Giaccari, Nicoletta Di Giorgi
Lipids in Health and Disease.2024;[Epub] CrossRef
Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
Journal of Lipid and Atherosclerosis.2023; 12(1): 12. CrossRef
Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement
Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon
Diabetes & Metabolism Journal.2023; 47(1): 1. CrossRef
Management of Dyslipidemia in Patients with Diabetes Mellitus
Kyung Ae Lee
The Journal of Korean Diabetes.2023; 24(3): 111. CrossRef
Association between carotid atherosclerosis and presence of intracranial atherosclerosis using three-dimensional high-resolution vessel wall magnetic resonance imaging in asymptomatic patients with type 2 diabetes
Ji Eun Jun, You-Cheol Hwang, Kyu Jeong Ahn, Ho Yeon Chung, Geon-Ho Jahng, Soonchan Park, In-Kyung Jeong, Chang-Woo Ryu
Diabetes Research and Clinical Practice.2022; 191: 110067. CrossRef

Review

Technology/Device
Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence: Sun Joon Moon, Inha Jung, Cheol-Young Park; Diabetes Metab J. 2021;45(6):813-839. Published online November 22, 2021; DOI: https://doi.org/10.4093/dmj.2021.0177

17,198 View
890 Download
42 Web of Science
39 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

Since Banting and Best isolated insulin in the 1920s, dramatic progress has been made in the treatment of type 1 diabetes mellitus (T1DM). However, dose titration and timely injection to maintain optimal glycemic control are often challenging for T1DM patients and their families because they require frequent blood glucose checks. In recent years, technological advances in insulin pumps and continuous glucose monitoring systems have created paradigm shifts in T1DM care that are being extended to develop artificial pancreas systems (APSs). Numerous studies that demonstrate the superiority of glycemic control offered by APSs over those offered by conventional treatment are still being published, and rapid commercialization and use in actual practice have already begun. Given this rapid development, keeping up with the latest knowledge in an organized way is confusing for both patients and medical staff. Herein, we explore the history, clinical evidence, and current state of APSs, focusing on various development groups and the commercialization status. We also discuss APS development in groups outside the usual T1DM patients and the administration of adjunct agents, such as amylin analogues, in APSs.

Citations

Citations to this article as recorded by

Integration of a Safety Module to Prevent Rebound Hypoglycemia in Closed-Loop Artificial Pancreas Systems
María F. Villa-Tamayo, Patricio Colmegna, Marc D. Breton
Journal of Diabetes Science and Technology.2024; 18(2): 318. CrossRef
The effects of acute hyperglycaemia on sports and exercise performance in type 1 diabetes: A systematic review and meta-analysis
Bonar McGuire, Hashim Dadah, Dominic Oliver
Journal of Science and Medicine in Sport.2024; 27(2): 78. CrossRef
A new approach to stabilize diabetes systems with time-varying delays and disturbance rejection
S. Syafiie, Fahd Alharbi, Abdullah Ali Alshehri, Bassam Hasanain
Journal of the Franklin Institute.2024; 361(1): 543. CrossRef
Effects of Low-Dose Glucagon on Subcutaneous Insulin Absorption in Pigs
Ingrid Anna Teigen, Marte Kierulf Åm, Misbah Riaz, Sverre Christian Christiansen, Sven Magnus Carlsen
Current Therapeutic Research.2024; 100: 100736. CrossRef
Enhancing equity in access to automated insulin delivery systems in an ethnically and socioeconomically diverse group of children with type 1 diabetes
John Pemberton, Louise Collins, Lesley Drummond, Renuka P Dias, Ruth Krone, Melanie Kershaw, Suma Uday
BMJ Open Diabetes Research & Care.2024; 12(3): e004045. CrossRef
Robust Online Correlation Method for Identification of a Nonparametric Model of Type 1 Diabetes
Martin Dodek, Eva Miklovičová
IEEE Access.2024; 12: 35899. CrossRef
Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial
Ji Yoon Kim, Sang-Man Jin, Eun Seok Kang, Soo Heon Kwak, Yeoree Yang, Jee Hee Yoo, Jae Hyun Bae, Jun Sung Moon, Chang Hee Jung, Ji Cheol Bae, Sunghwan Suh, Sun Joon Moon, Sun Ok Song, Suk Chon, Jae Hyeon Kim
Diabetologia.2024; 67(7): 1235. CrossRef
Prevention and treatment of type 1 diabetes: in search of the ideal combination therapy targeting multiple immunometabolic pathways
Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro, Maria Luisa Garo, Donatella Pastore, Francesca Pacifici, Camillo Ricordi, David Della-Morte, Marco Infante
Metabolism and Target Organ Damage.2024;[Epub] CrossRef
Mitigating diabetes associated with reactive oxygen species (ROS) and protein aggregation through pharmacological interventions
Giulia Bennici, Hanan Almahasheer, Mawadda Alghrably, Daniela Valensin, Arian Kola, Chrysoula Kokotidou, Joanna Lachowicz, Mariusz Jaremko
RSC Advances.2024; 14(25): 17448. CrossRef
Real‐world glycaemic outcomes of automated insulin delivery in type 1 diabetes: A meta‐analysis
Qin Yang, Baoqi Zeng, Jiayi Hao, Qingqing Yang, Feng Sun
Diabetes, Obesity and Metabolism.2024; 26(9): 3753. CrossRef
Efficacy of advanced hybrid closed loop systems in cystic fibrosis related diabetes: a pilot study
Marta Bassi, Daniele Franzone, Francesca Dufour, Giordano Spacco, Federico Cresta, Giuseppe d’Annunzio, Giacomo Tantari, Maria Grazia Calevo, Carlo Castellani, Nicola Minuto, Rosaria Casciaro
Frontiers in Endocrinology.2024;[Epub] CrossRef
Emerging Technologies in Endocrine Drug Delivery: Innovations for Improved Patient Care
Mahvish Renzu, Carly Hubers, Kendall Conway, Viktoriya Gibatova, Vidhi Mehta, Wael Taha
Cureus.2024;[Epub] CrossRef
A stochastic model-based control methodology for glycemic management in the intensive care unit
Melike Sirlanci, George Hripcsak, Cecilia C. Low Wang, J. N. Stroh, Yanran Wang, Tellen D. Bennett, Andrew M. Stuart, David J. Albers
Frontiers in Medical Engineering.2024;[Epub] CrossRef
Advances in Type 1 Diabetes Mellitus Management in Children
Mridu Bahal, Vineeta Pande, Jasleen Dua, Shailaja Mane
Cureus.2024;[Epub] CrossRef
Expansion of the Pancreas Transplant Recipient Pool: Appropriate for Most or Are There Limits?
Jonathan A. Fridell, Robert J. Stratta
Current Transplantation Reports.2024;[Epub] CrossRef
Reinforcement Learning: A Paradigm Shift in Personalized Blood Glucose Management for Diabetes
Lehel Dénes-Fazakas, László Szilágyi, Levente Kovács, Andrea De Gaetano, György Eigner
Biomedicines.2024; 12(9): 2143. CrossRef
100 Years of insulin: A chemical engineering perspective
B. Wayne Bequette
Korean Journal of Chemical Engineering.2023; 40(1): 1. CrossRef
Efficacy of intermittent short‐term use of a real‐time continuous glucose monitoring system in non‐insulin–treated patients with type 2 diabetes: A randomized controlled trial
Sun Joon Moon, Kyung‐Soo Kim, Woo Je Lee, Mi Yeon Lee, Robert Vigersky, Cheol‐Young Park
Diabetes, Obesity and Metabolism.2023; 25(1): 110. CrossRef
Identifiable prediction animal model for the bi-hormonal intraperitoneal artificial pancreas
Karim Davari Benam, Hasti Khoshamadi, Marte Kierulf Åm, Øyvind Stavdahl, Sebastien Gros, Anders Lyngvi Fougner
Journal of Process Control.2023; 121: 13. CrossRef
Advances in Continuous Glucose Monitoring and Integrated Devices for Management of Diabetes with Insulin-Based Therapy: Improvement in Glycemic Control
Jee Hee Yoo, Jae Hyeon Kim
Diabetes & Metabolism Journal.2023; 47(1): 27. CrossRef
CGM accuracy: Contrasting CE marking with the governmental controls of the USA (FDA) and Australia (TGA): A narrative review
John S Pemberton, Emma G Wilmot, Katharine Barnard‐Kelly, Lalantha Leelarathna, Nick Oliver, Tabitha Randell, Craig E Taplin, Pratik Choudhary, Peter Adolfsson
Diabetes, Obesity and Metabolism.2023; 25(4): 916. CrossRef
Evaluation of awareness and attitude of paediatric nursing students, nurses, and adolescents regarding type one diabetes advanced devices and virtual nursing
Howaida Moawad Ahmed Ali
Kontakt.2023; 25(2): 100. CrossRef
Predicting the output error of the suboptimal state estimator to improve the performance of the MPC-based artificial pancreas
Martin Dodek, Eva Miklovičová
Control Theory and Technology.2023; 21(4): 541. CrossRef
A Markov Model of Gap Occurrence in Continuous Glucose Monitoring Data for Realistic in Silico Clinical Trials
Martina Vettoretti, Martina Drecogna, Simone Del Favero, Andrea Facchinetti, Giovanni Sparacino
Computer Methods and Programs in Biomedicine.2023; 240: 107700. CrossRef
Drug delivery breakthrough technologies – A perspective on clinical and societal impact
Beate Bittner, Manuel Sánchez-Félix, Dennis Lee, Athanas Koynov, Joshua Horvath, Felix Schumacher, Simon Matoori
Journal of Controlled Release.2023; 360: 335. CrossRef
Importance of continuous glucose monitoring in the treatment of diabetes mellitus
Sun Joon Moon, Won-Young Lee
Journal of the Korean Medical Association.2023; 66(7): 432. CrossRef
Constrained Versus Unconstrained Model Predictive Control for Artificial Pancreas
Chiara Toffanin, Lalo Magni
IEEE Transactions on Control Systems Technology.2023; 31(5): 2288. CrossRef
Intelligent Insulin vs. Artificial Intelligence for Type 1 Diabetes: Will the Real Winner Please Stand Up?
Valentina Maria Cambuli, Marco Giorgio Baroni
International Journal of Molecular Sciences.2023; 24(17): 13139. CrossRef
Artificial Intelligence in Efficient Diabetes Care
Gopal Bhagwan Khodve, Sugato Banerjee
Current Diabetes Reviews.2023;[Epub] CrossRef
The artificial pancreas: two alternative approaches to achieve a fully closed-loop system with optimal glucose control
M. K. Åm, I. A. Teigen, M. Riaz, A. L. Fougner, S. C. Christiansen, S. M. Carlsen
Journal of Endocrinological Investigation.2023; 47(3): 513. CrossRef
Multivariable Automated Insulin Delivery System for Handling Planned and Spontaneous Physical Activities
Mohammad Reza Askari, Mohammad Ahmadasas, Andrew Shahidehpour, Mudassir Rashid, Laurie Quinn, Minsun Park, Ali Cinar
Journal of Diabetes Science and Technology.2023; 17(6): 1456. CrossRef
Advanced Technology (Continuous Glucose Monitoring and Advanced Hybrid Closed-Loop Systems) in Diabetes from the Perspective of Gender Differences
Maria Grazia Nuzzo, Marciano Schettino
Diabetology.2023; 4(4): 519. CrossRef
Artificial Pancreas under a Zone Model Predictive Control based on Gaussian Process models: toward the personalization of the closed loop
Marco Polver, Beatrice Sonzogni, Mirko Mazzoleni, Fabio Previdi, Antonio Ferramosca
IFAC-PapersOnLine.2023; 56(2): 9642. CrossRef
Personalized Constrained MPC for glucose regulation
Chiara Toffanin, Lalo Magni
IFAC-PapersOnLine.2023; 56(2): 9648. CrossRef
Automated Insulin Delivery Systems in Children and Adolescents With Type 1 Diabetes: A Systematic Review and Meta-analysis of Outpatient Randomized Controlled Trials
Baoqi Zeng, Le Gao, Qingqing Yang, Hao Jia, Feng Sun
Diabetes Care.2023; 46(12): 2300. CrossRef
Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study
Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon
Frontiers in Endocrinology.2022;[Epub] CrossRef
Dual‐hormone artificial pancreas for glucose control in type 1 diabetes: A meta‐analysis
Baoqi Zeng, Hao Jia, Le Gao, Qingqing Yang, Kai Yu, Feng Sun
Diabetes, Obesity and Metabolism.2022; 24(10): 1967. CrossRef
Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Systematic Review
Alezandra Torres-Castaño, Amado Rivero-Santana, Lilisbeth Perestelo-Pérez, Andrea Duarte-Díaz, Analia Abt-Sacks, Vanesa Ramos-García, Yolanda Álvarez-Pérez, Ana M. Wäagner, Mercedes Rigla, Pedro Serrano-Aguilar
Applied Sciences.2022; 12(20): 10262. CrossRef
History of insulin treatment of pediatric patients with diabetes in Korea
Jae Hyun Kim, Choong Ho Shin, Sei Won Yang
Annals of Pediatric Endocrinology & Metabolism.2021; 26(4): 237. CrossRef

Original Article

Drug/Regimen
Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors: Sangmo Hong, Chang Hee Jung, Song Han, Cheol-Young Park; Diabetes Metab J. 2022;46(1):63-70. Published online April 19, 2021; DOI: https://doi.org/10.4093/dmj.2020.0253

65,535 View
298 Download

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub: Background
It is not known which type 2 diabetes mellitus (T2DM) patients would most benefit from dipeptidyl peptidase-4 (DPP-4) inhibitor treatment. We aimed to investigate the predictors of response to DPP-4 inhibitors considering degree of DPP-4 inhibition.
Methods
This study is a post hoc analysis of a 24-week, randomized, double-blind, phase III trial that compared the efficacy and safety of a DPP-4 inhibitor (gemigliptin vs. sitagliptin) in patients with T2DM. Subjects were classified into tertiles of T1 <65.26%, T2=65.26%–76.35%, and T3 ≥76.35% by DPP-4 inhibition. We analyzed the change from baseline in glycosylated hemoglobin (HbA1c) according to DPP-4 inhibition with multiple linear regression adjusting for age, ethnicity, body mass index, baseline HbA1c, and DPP-4 activity at baseline.
Results
The mean age was greater in the high tertile group compared with the low tertile group (T1: 49.8±8.3 vs. T2: 53.1±10.5 vs. T3: 55.3±9.5, P<0.001) of DPP-4 inhibition. Although HbA1c at baseline was not different among tertiles of DPP-4 inhibition (P=0.398), HbA1c after 24-week treatment was lower in the higher tertile compares to the lower tertile (T1: 7.30%±0.88% vs. T2: 7.12%±0.78% vs. T3: 7.00%±0.78%, P=0.021). In multiple regression analysis, DPP-4 enzyme inhibition rate was not a significant determent for HbA1c reduction due to age. In subgroup analysis by tertile of DPP-4 inhibition, age was the only significant predictor and only in the highest tertile (R²=0.281, B=–0.014, P=0.024).
Conclusion
This study showed that HbA1c reduction by DPP-4 inhibitor was associated with increasing age, and this association was linked with higher DPP-4 inhibition.

Review

Guideline/Fact Sheet
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association: Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee, Korean Diabetes Association (KDA) Fatty Liver Research Group; Diabetes Metab J. 2020;44(3):382-401. Published online May 11, 2020; DOI: https://doi.org/10.4093/dmj.2020.0010

13,722 View
375 Download
45 Web of Science
46 Crossref

Abstract PDF PubReader

This clinical practice position statement, a product of the Fatty Liver Research Group of the Korean Diabetes Association, proposes recommendations for the diagnosis, progression and/or severity assessment, management, and follow-up of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). Patients with both T2DM and NAFLD have an increased risk of non-alcoholic steatohepatitis (NASH) and fibrosis and a higher risk of cardiovascular diseases and diabetic complications compared to those without NAFLD. With regards to the evaluation of patients with T2DM and NAFLD, ultrasonography-based stepwise approaches using noninvasive biomarker models such as fibrosis-4 or the NAFLD fibrosis score as well as imaging studies such as vibration-controlled transient elastography with controlled attenuation parameter or magnetic resonance imaging-proton density fat fraction are recommended. After the diagnosis of NAFLD, the stage of fibrosis needs to be assessed appropriately. For management, weight reduction achieved by lifestyle modification has proven beneficial and is recommended in combination with antidiabetic agent(s). Evidence that some antidiabetic agents improve NAFLD/NASH with fibrosis in patients with T2DM is emerging. However, there are currently no definite pharmacologic treatments for NAFLD in patients with T2DM. For specific cases, bariatric surgery may be an option if indicated.

Citations

Citations to this article as recorded by

A combined extract containing Schisandra chinensis (SCE) reduced hepatic triglyceride accumulation in rats fed a high-sucrose diet
Haneul Lee, Eun Young Kang, Joowon Lee, Yejin Kim, Sumin Kang, Hayoon Kim, Hyun Kyung Kim, Gyoungok Gang, Sang-gil Lee, Cao Lei, Gwang-woong Go
Food Science and Biotechnology.2024; 33(6): 1449. CrossRef
Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
BMJ.2024; : e076388. CrossRef
Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
Inha Jung, Dae-Jeong Koo, Won-Young Lee
Diabetes & Metabolism Journal.2024; 48(3): 327. CrossRef
Association between urinary polycyclic aromatic hydrocarbons and risk of metabolic associated fatty liver disease
Minzhen Wang, Shaoyan Tang, Lulu Zhang, Yamin Zhao, Yindi Peng, Shan zheng, Zanchao Liu
International Archives of Occupational and Environmental Health.2024; 97(7): 695. CrossRef
A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease
Seung Joon Choi, Sungjin Yoon, Kyoung-Kon Kim, Doojin Kim, Hye Eun Lee, Kwang Gi Kim, Seung Kak Shin, Ie Byung Park, Seong Min Kim, Dae Ho Lee
Diabetes & Metabolism Journal.2024; 48(4): 740. CrossRef
Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy
Xi Lu, Qingxing Xie, Xiaohui Pan, Ruining Zhang, Xinyi Zhang, Ge Peng, Yuwei Zhang, Sumin Shen, Nanwei Tong
Signal Transduction and Targeted Therapy.2024;[Epub] CrossRef
Risk Scores for Prediction of Major Cardiovascular Events in Non-Alcoholic Fatty Liver Disease: A No Man’s Land?
Liliana Gheorghe, Roxana Nemteanu, Andreea Clim, Gina Eosefina Botnariu, Irina Iuliana Costache, Alina Plesa
Life.2023; 13(4): 857. CrossRef
Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
Metabolism.2023; 145: 155612. CrossRef
Association between fatty liver index and risk of end-stage renal disease stratified by kidney function in patients with type 2 diabetes: A nationwide population-based study
Goh Eun Chung, Kyungdo Han, Kyu-Na Lee, Jung Ho Bae, Sun Young Yang, Su-Yeon Choi, Jeong Yoon Yim, Nam Ju Heo
Diabetes & Metabolism.2023; 49(4): 101454. CrossRef
Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis
Min Jeong Park, Hayeon Kim, Myeong Gyu Kim, Kyungim Kim
Clinical and Molecular Hepatology.2023; 29(3): 693. CrossRef
Histological analysis of hypoglycemic agents on liver fibrosis in patients with non-alcoholic fatty liver disease: a systematic review
Qingxing Xie, Xiaohui Pan, Xinyue Zhang, Jinfang Ma, Ge Peng, Nanwei Tong
Chinese Medical Journal.2023; 136(16): 2014. CrossRef
Hepatotropc effects of glucose-lowering drugs: non-alcoholic fatty liver disease in focus
E. V. Uzhakova, Z. E. Zshanko, E. N. Smirnova
Experimental and Clinical Gastroenterology.2023; (6): 121. CrossRef
Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model
Yun Kyung Lee, Tae Jung Oh, Ji In Lee, Bo Yoon Choi, Hyen Chung Cho, Hak Chul Jang, Sung Hee Choi
European Journal of Pharmacology.2023; 957: 175946. CrossRef
Hepatic T-cell senescence and exhaustion are implicated in the progression of fatty liver disease in patients with type 2 diabetes and mouse model with nonalcoholic steatohepatitis
Byeong Chang Sim, Yea Eun Kang, Sun Kyoung You, Seong Eun Lee, Ha Thi Nga, Ho Yeop Lee, Thi Linh Nguyen, Ji Sun Moon, Jingwen Tian, Hyo Ju Jang, Jeong Eun Lee, Hyon-Seung Yi
Cell Death & Disease.2023;[Epub] CrossRef
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Nan Hee Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, YoonJu Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang Youl Rhee, Hae J
Diabetes & Metabolism Journal.2023; 47(5): 575. CrossRef
Circ_0004535/miR-1827/CASP8 network involved in type 2 diabetes mellitus with nonalcoholic fatty liver disease
Min Li, Ai Zeng, Xinle Tang, Hui Xu, Wei Xiong, Yanying Guo
Scientific Reports.2023;[Epub] CrossRef
Stratification by obesity class, rather than age, can identify a higher percent of children at risk for non‐alcoholic fatty liver disease and metabolic dysfunction
Aurelia Radulescu, Adam J. Dugan, Mary Killian, Suzanna L. Attia, Marialena Mouzaki, George J. Fuchs, Rohit Kohli, Henrietta Bada, Philip A. Kern, Samir Softic
Pediatric Obesity.2022;[Epub] CrossRef
Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus
Hae Kyung Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
Diabetes & Metabolism Journal.2022; 46(1): 104. CrossRef
Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway
Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
Endocrinology and Metabolism.2022; 37(1): 74. CrossRef
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Yongin Cho, Yong-ho Lee
Endocrinology and Metabolism.2022; 37(1): 38. CrossRef
Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)
Yongin Cho, Hyungjin Rhee, Young-eun Kim, Minyoung Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Jin-Young Choi, Yong-ho Lee
BMC Medicine.2022;[Epub] CrossRef
Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee
Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241. CrossRef
Anti-Obesity and Anti-Hyperglycemic Effects of Meretrix lusoria Protamex Hydrolysate in ob/ob Mice
Min Ju Kim, Ramakrishna Chilakala, Hee Geun Jo, Seung-Jae Lee, Dong-Sung Lee, Sun Hee Cheong
International Journal of Molecular Sciences.2022; 23(7): 4015. CrossRef
The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
Jiyun Park, Gyuri Kim, Bong-Sung Kim, Kyung-Do Han, So Yoon Kwon, So Hee Park, You-Bin Lee, Sang-Man Jin, Jae Hyeon Kim
Cardiovascular Diabetology.2022;[Epub] CrossRef
Cumulative Exposure to High γ-Glutamyl Transferase Level and Risk of Diabetes: A Nationwide Population-Based Study
Ji-Yeon Park, Kyungdo Han, Hun-Sung Kim, Jae-Hyoung Cho, Kun-Ho Yoon, Mee Kyoung Kim, Seung-Hwan Lee
Endocrinology and Metabolism.2022; 37(2): 272. CrossRef
SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
Jun Sung Moon, Jun Hwa Hong, Yong Jin Jung, Ele Ferrannini, Michael A. Nauck, Soo Lim
Trends in Endocrinology & Metabolism.2022; 33(6): 424. CrossRef
Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis
Aron Park, Seung Joon Choi, Sungjin Park, Seong Min Kim, Hye Eun Lee, Minjae Joo, Kyoung Kon Kim, Doojin Kim, Dong Hae Chung, Jae Been Im, Jaehun Jung, Seung Kak Shin, Byung-Chul Oh, Cheolsoo Choi, Seungyoon Nam, Dae Ho Lee
International Journal of Molecular Sciences.2022; 23(9): 5035. CrossRef
Chinese Herbal Medicine for Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Sihan Peng, Lu Liu, Ziyan Xie, Xiyu Zhang, Chunguang Xie, Sha Ye, Xiangeng Zhang, Xiaoli Liang, Hongyan Wang, Ya Liu
Frontiers in Pharmacology.2022;[Epub] CrossRef
Non-alcoholic fatty liver disease and sarcopenia is associated with the risk of albuminuria independent of insulin resistance, and obesity
Eugene Han, Mi Kyung Kim, Seung-Soon Im, Byoung Kuk Jang, Hye Soon Kim
Journal of Diabetes and its Complications.2022; 36(8): 108253. CrossRef
Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
Eun-Jung Rhee
Endocrinology and Metabolism.2022; 37(3): 415. CrossRef
Plasma Metabolomics and Machine Learning-Driven Novel Diagnostic Signature for Non-Alcoholic Steatohepatitis
Moongi Ji, Yunju Jo, Seung Joon Choi, Seong Min Kim, Kyoung Kon Kim, Byung-Chul Oh, Dongryeol Ryu, Man-Jeong Paik, Dae Ho Lee
Biomedicines.2022; 10(7): 1669. CrossRef
Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes
Yewon Na, Soo Wan Kim, Ie Byung Park, Soo Jung Choi, Seungyoon Nam, Jaehun Jung, Dae Ho Lee
The Journal of Clinical Endocrinology & Metabolism.2022; 107(11): 3022. CrossRef
Nonalcoholic fatty liver disease is associated with early left ventricular diastolic dysfunction in patients with type 2 diabeteS
Walaa Sheba, Eman Morsy, Salah Altahan, Mona Ayaad, Sameh A. Lashen
Alexandria Journal of Medicine.2022; 58(1): 117. CrossRef
The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 Diabetes: A nationwide cohort study
Jiyun Park, Gyuri Kim, Bong-Sung Kim, Kyung-Do Han, So Yoon Kwon, So Hee Park, You-Bin Lee, Sang-Man Jin, Jae Hyeon Kim
Diabetes Research and Clinical Practice.2022; 194: 110191. CrossRef
Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9)
Ji Hye Huh
Diabetes & Metabolism Journal.2022; 46(6): 953. CrossRef
The association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study
Goh Eun Chung, Su-Min Jeong, Eun Ju Cho, Ji Won Yoon, Jeong-Ju Yoo, Yuri Cho, Kyu-na Lee, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu
Cardiovascular Diabetology.2022;[Epub] CrossRef
Non-Albumin Proteinuria (NAP) as a Complementary Marker for Diabetic Kidney Disease (DKD)
Jaehyun Bae, Young Jun Won, Byung-Wan Lee
Life.2021; 11(3): 224. CrossRef
Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
Sook Jung Lee, Byung-Wan Lee
The Journal of Korean Diabetes.2021; 22(1): 38. CrossRef
Non-alcoholic fatty liver disease
Elizabeth E Powell, Vincent Wai-Sun Wong, Mary Rinella
The Lancet.2021; 397(10290): 2212. CrossRef
Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway
In-Jin Cho, Da-Hee Oh, Jin Yoo, You-Cheol Hwang, Kyu Jeung Ahn, Ho-Yeon Chung, Soung Won Jeong, Ju-Young Moon, Sang-Ho Lee, Sung-Jig Lim, In-Kyung Jeong
Scientific Reports.2021;[Epub] CrossRef
Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya
Russian Journal of Gastroenterology, Hepatology, Coloproctology.2021; 31(2): 14. CrossRef
Liver Fibrosis Indices for the Prediction of Mortality in Korean Subjects: A 16-Year Prospective Cohort Study
Tae Jung Oh, Kyuho Kim, Jae Hoon Moon, Sung Hee Choi, Nam H Cho, Hak Chul Jang
Journal of the Endocrine Society.2021;[Epub] CrossRef
Reduced Rank Regression-Derived Dietary Patterns Related to the Fatty Liver Index and Associations with Type 2 Diabetes Mellitus among Ghanaian Populations under Transition: The RODAM Study
Tracy Bonsu Osei, Anne-Marieke van Dijk, Sjoerd Dingerink, Felix Patience Chilunga, Erik Beune, Karlijn Anna Catharina Meeks, Silver Bahendeka, Matthias Bernd Schulze, Charles Agyemang, Mary Nicolaou, Adriaan Georgius Holleboom, Ina Danquah
Nutrients.2021; 13(11): 3679. CrossRef
Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
Frontiers in Endocrinology.2021;[Epub] CrossRef
Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes
Kyuho Kim, Tae Jung Oh, Hyen Chung Cho, Yun Kyung Lee, Chang Ho Ahn, Bo Kyung Koo, Jae Hoon Moon, Sung Hee Choi, Hak Chul Jang
Scientific Reports.2021;[Epub] CrossRef
Evaluation of Grapefruit Juice in terms of Interleukin 18 Gene Expression in Rats with Fatty Liver and Healthy Rats
Simin Bahmanpoor, Noosha Zia-Jahromi
journal of ilam university of medical sciences.2021; 29(4): 74. CrossRef

Corrigendum

Corrigenda: Table Correction. Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis: Yong-ho Lee, Yongin Cho, Byung-Wan Lee, Cheol-Young Park, Dae Ho Lee, Bong-Soo Cha, Eun-Jung Rhee; Diabetes Metab J. 2019;43(5):731-731. Published online October 24, 2019; DOI: https://doi.org/10.4093/dmj.2019.0188; Corrects: Diabetes Metab J 2019;43(1):31

3,826 View
46 Download
1 Web of Science
2 Crossref

PDF PubReader

Citations

Citations to this article as recorded by

Association of statins with nonalcoholic fatty liver disease in patients with diabetes
Raj Shah, Alexander Kong, Silvio De Melo, Moheb Boktor, Richard Henriquez, Amar Mandalia, Hrishikesh Samant, Carlos A. Alvarez, Ishak A. Mansi
Journal of Investigative Medicine.2024; 72(6): 497. CrossRef
Comparing the Risk of Poor Outcomes Among Hepatitis C–Infected, Cured, and Never-Infected Controls
Varun Saxena, Weilu Wu, Sreepriya Balasubramanian, Nizar Mukhtar, Suk I. Seo, Joanna B. Ready, Brock A. MacDonald, Julie A. Schmittdiel
Gastro Hep Advances.2024; 3(6): 871. CrossRef

Reviews

Clinical Diabetes & Therapeutics
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment: Kyung-Soo Kim, Byung-Wan Lee, Yong Jin Kim, Dae Ho Lee, Bong-Soo Cha, Cheol-Young Park; Diabetes Metab J. 2019;43(2):127-143. Published online April 15, 2019; DOI: https://doi.org/10.4093/dmj.2019.0034

8,942 View
165 Download
28 Web of Science
37 Crossref

Abstract PDF PubReader

Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to date. However, it is not easy to maintain weight loss by lifestyle modification alone; pharmacological treatments are helpful in this regard. Although many drugs have been investigated, pioglitazone could be a first-line therapy in patients with NAFLD and diabetes. Many more drugs are currently being developed and investigated, and it is likely that combination strategies will be used for future treatment of NAFLD and diabetes. Attention should be paid to the management of NAFLD and diabetes and efforts should be made to intervene early and individualize treatment of NAFLD in patients with diabetes.

Citations

Citations to this article as recorded by

Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
BMJ.2024; : e076388. CrossRef
The Efficacy of Empagliflozin in Combination with Pioglitazone on the Improvement of Fatty Liver Disease in Patients with Type 2 Diabetes
Morteza Aghajanpoor, Mehrzad Gholampourdehaki, Reza Mosaed, Iraj Mirzaii-Dizgah, Afsaneh Vosughi
Annals of Military and Health Sciences Research.2024;[Epub] CrossRef
Research Progress of Traditional Chinese Medicine and Western Medicine on Non-Alcoholic Fatty Liver Disease
强江郭
Advances in Clinical Medicine.2024; 14(03): 561. CrossRef
Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: Bi-directional opportunities to multiply preventive strategies
Alhussain Yasin, Madison Nguyen, Angad Sidhu, Priyanka Majety, Jared Spitz, Amon Asgharpour, Mohammad S. Siddiqui, Laurence S. Sperling, Arshed A. Quyyumi, Anurag Mehta
Diabetes Research and Clinical Practice.2024; 211: 111650. CrossRef
Effect of ipragliflozin on liver enzymes in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
Rizwana Parveen, Shadan Hussain, Sparsh Saini, Parvej Khan, Nilanjan Saha, Nidhi
Expert Opinion on Pharmacotherapy.2024; 25(7): 925. CrossRef
Effect of aerobic training with silymarin consumption on glycemic indices and liver enzymes in men with type 2 diabetes
Keyvan Ghalandari, Mojtaba Shabani, Ali Khajehlandi, Amin Mohammadi
Archives of Physiology and Biochemistry.2023; 129(1): 76. CrossRef
Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
Diabetes & Metabolism Journal.2023; 47(2): 220. CrossRef
Comparative antihypertensive efficacy of combinations of azilsartan medoxomil or olmesartan medoxomil with amlodipine in patients with arterial hypertension, type 2 diabetes mellitus and non-alcoholic fatty liver disease
I. А. Lukonin, V. V. Skibitsky, A. V. Fendrikova, A. V. Skibitsky, I. A. Antipov
South Russian Journal of Therapeutic Practice.2023; 4(1): 68. CrossRef
An Ethyl Acetate Extract of Eryngium carlinae Inflorescences Attenuates Oxidative Stress and Inflammation in the Liver of Streptozotocin-Induced Diabetic Rats
Cristian M. Trejo-Hurtado, Cinthia I. Landa-Moreno, Jenaro Lemus-de la Cruz, Donovan J. Peña-Montes, Rocío Montoya-Pérez, Rafael Salgado-Garciglia, Salvador Manzo-Avalos, Christian Cortés-Rojo, Juan Luis Monribot-Villanueva, José Antonio Guerrero-Analco,
Antioxidants.2023; 12(6): 1235. CrossRef
Pharmacogenetics of glucagon-like peptide-1 agonists in the treatment of type 2 diabetes mellitus
Iu.G. Samoilova, A.E. Stankova, M.V. Matveeva, O.E. Vaizova, D.V. Podchinenova, D.A. Kudlay, T.A. Filippova, I.R. Grishkevich
Profilakticheskaya meditsina.2023; 26(12): 95. CrossRef
Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee
Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241. CrossRef
Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park
Obesity.2022; 30(6): 1279. CrossRef
Evaluating Triglyceride and Glucose Index as a Simple and Easy-to-Calculate Marker for All-Cause and Cardiovascular Mortality
Kyung-Soo Kim, Sangmo Hong, You-Cheol Hwang, Hong-Yup Ahn, Cheol-Young Park
Journal of General Internal Medicine.2022; 37(16): 4153. CrossRef
Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents
Kyung-Soo Kim
The Journal of Korean Diabetes.2022; 23(2): 83. CrossRef
Efficacy and mechanism of Jiedu Tongluo Tiaogan Formula in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease: Study protocol for a parallel-armed, randomized controlled trial
Jinghan Xu, Chunli Piao, Yue Qu, Tianjiao Liu, Yuting Peng, Qi Li, Xiaohua Zhao, Pei Li, Xuemin Wu, Yawen Fan, Binqin Chen, Jie Yang
Frontiers in Pharmacology.2022;[Epub] CrossRef
Intestinal microbiota in the treatment of metabolically associated fatty liver disease
Ji-Shuai Wang, Jin-Chun Liu
World Journal of Clinical Cases.2022; 10(31): 11240. CrossRef
Efficiency of combined antihypertensive pharmacotherapy in patients with arterial hypertension, combined with type 2 diabetes mellitus and non-alcoholic fatty liver disease
I. A. Lukonin, V. V. Skibitsky, A. V. Fendrikova, I. I. Pavlyuchenko, K. Yu. Lazarev, F. A. Kovalenko
Systemic Hypertension.2022; 19(1): 31. CrossRef
Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats
Yujie Zhong, Zhiman Li, Ruyi Jin, Yanpeng Yao, Silan He, Min Lei, Xin Wang, Chao Shi, Li Gao, Xiaoli Peng
Nutrients.2022; 14(23): 4994. CrossRef
Pluchea indica Leaf Extract Alleviates Dyslipidemia and Hepatic Steatosis by Modifying the Expression of Lipid Metabolism-Related Genes in Rats Fed a High Fat-High Fructose Diet
Patcharin Singdam, Jarinyaporn Naowaboot, Laddawan Senggunprai, Kampeebhorn Boonloh, Patchareewan Pannangpetch
Preventive Nutrition and Food Science.2022; 27(4): 384. CrossRef
NAFLDin type 2 diabetes mellitus: Still many challenging questions
Simona Cernea, Itamar Raz
Diabetes/Metabolism Research and Reviews.2021;[Epub] CrossRef
Umbilical Cord-Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 Cell
Kyung-Soo Kim, Yeon Kyung Choi, Mi Jin Kim, Jung Wook Hwang, Kyunghoon Min, Sang Youn Jung, Soo-Kyung Kim, Yong-Soo Choi, Yong-Wook Cho
Diabetes & Metabolism Journal.2021; 45(2): 260. CrossRef
Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
Diabetes Therapy.2021; 12(1): 171. CrossRef
Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
Sook Jung Lee, Byung-Wan Lee
The Journal of Korean Diabetes.2021; 22(1): 38. CrossRef
Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya
Russian Journal of Gastroenterology, Hepatology, Coloproctology.2021; 31(2): 14. CrossRef
NAFLD and its link with diabetes: Why we should be worried
Louise Cremonesini, Emma Harkin
Independent Nurse.2021; 2021(8): 20. CrossRef
Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Eugene Han, Mi Kyung Kim, Byoung Kuk Jang, Hye Soon Kim
Diabetes & Metabolism Journal.2021; 45(5): 698. CrossRef
Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study
Jun Hyung Kim, Jin Sil Moon, Seok Joon Byun, Jun Hyeok Lee, Dae Ryong Kang, Ki Chul Sung, Jang Young Kim, Ji Hye Huh
Cardiovascular Diabetology.2020;[Epub] CrossRef
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
Rohit Loomba, Erin Morgan, Lynnetta Watts, Shuting Xia, Lisa A Hannan, Richard S Geary, Brenda F Baker, Sanjay Bhanot
The Lancet Gastroenterology & Hepatology.2020; 5(9): 829. CrossRef
Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
Eugene Han, Yongin Cho, Kyung-won Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-wan Lee
Medicine.2020; 99(33): e21038. CrossRef
Metabolic liver disease in diabetes – From mechanisms to clinical trials
Bedair Dewidar, Sabine Kahl, Kalliopi Pafili, Michael Roden
Metabolism.2020; 111: 154299. CrossRef
Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review
Siôn A. Parry, Leanne Hodson
Advances in Therapy.2020; 37(4): 1381. CrossRef
Diabetes and Metabolism Journal in 2020: Good to Great
In-Kyung Jeong
Diabetes & Metabolism Journal.2020; 44(1): 1. CrossRef
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee
Diabetes & Metabolism Journal.2020; 44(3): 382. CrossRef
Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies
Chang-hua Zhang, Bu-gao Zhou, Jun-qing Sheng, Yang Chen, Ying-qian Cao, Chen Chen
Pharmacological Research.2020; 159: 104984. CrossRef
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung-Soo Kim, Byung-Wan Lee
Clinical and Molecular Hepatology.2020; 26(4): 430. CrossRef
Effects of sodium–glucose cotransporter 2 inhibitors on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
Baodi Xing, Yuhang Zhao, Bingzi Dong, Yue Zhou, Wenshan Lv, Wenjuan Zhao
Journal of Diabetes Investigation.2020; 11(5): 1238. CrossRef
Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress
Tamiris Ingrid Petito-da-Silva, Vanessa Souza-Mello, Sandra Barbosa-da-Silva
Molecular and Cellular Endocrinology.2019; 498: 110539. CrossRef

Complications
Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis: Yong-ho Lee, Yongin Cho, Byung-Wan Lee, Cheol-Young Park, Dae Ho Lee, Bong-Soo Cha, Eun-Jung Rhee; Diabetes Metab J. 2019;43(1):31-45. Published online December 17, 2018; DOI: https://doi.org/10.4093/dmj.2019.0011; Correction in: Diabetes Metab J 2019;43(5):731

9,656 View
187 Download
115 Web of Science
111 Crossref

Abstract PDF PubReader

Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders whose prevalence rates are expected to rise worldwide, corresponding to aging and increasingly obese populations. Compared to the general population (around 25%), 50% to 70% of people with diabetes have NAFLD, and NAFLD severity (including fibrosis) tends to be worsened by the presence of diabetes. NAFLD is considered an emerging risk factor for type 2 diabetes mellitus and a contributor to the development of chronic diabetes-related complications. This reciprocal relationship demonstrates the importance of confirming suspected NAFLD in patients with diabetes. Due to the invasive nature of liver biopsy to assess NAFLD status, various alternative non-invasive modalities have been developed and validated. Here, we summarized the epidemiology of NAFLD in patients with diabetes and reviewed currently available imaging modalities and biomarker-based prediction models for their ability to detect liver steatosis and/or fibrosis.

Citations

Citations to this article as recorded by

Recent advances and potentiality of postbiotics in the food industry: Composition, inactivation methods, current applications in metabolic syndrome, and future trends
Yujie Zhong, Tao Wang, Ruilin Luo, Jiayu Liu, Ruyi Jin, Xiaoli Peng
Critical Reviews in Food Science and Nutrition.2024; 64(17): 5768. CrossRef
Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim
Metabolism.2024; 152: 155789. CrossRef
Intact ketogenesis predicted reduced risk of moderate-severe metabolic-associated fatty liver disease assessed by liver transient elastography in newly diagnosed type 2 diabetes
Sejeong Lee, Jaehyun Bae, Seung Up Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
Frontiers in Endocrinology.2024;[Epub] CrossRef
ZJU Index as a Predictive Tool for Diabetes Incidence: Insights from a Population-Based Cohort Study
Chenjiao Wu, Yi Hao Loh, Hangkai Huang, Chengfu Xu
Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 715. CrossRef
Genetically engineered long-acting Esculentin-2CHa(1−30) fusion protein with potential applicability for the treatment of NAFLD
Jaewoong Lee, Reeju Amatya, Kyung Eun Kim, Young-Hoon Park, Eunmi Hong, Krismala Djayanti, Kyoung Ah Min, Gu Seob Roh, Meong Cheol Shin
Journal of Controlled Release.2024; 372: 699. CrossRef
Sigmoidal relationship between liver fat content and nonalcoholic fatty liver disease in Chinese adults
Pingping Yu, Huachao Yang, Hu Li, Ying Mei, Yuanyuan Wu, Hongfeng Cheng, Huiru Su, Yueling Deng, Tao Jiang, Zhongxiang He, Peng Hu
Postgraduate Medical Journal.2024; 100(1186): 562. CrossRef
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
Stephen A. Harrison, Juan P. Frias, K. Jean Lucas, Gary Reiss, Guy Neff, Sureka Bollepalli, Yan Su, Doreen Chan, Erik J. Tillman, Ali Moulton, Brittany de Temple, Arian Zari, Reshma Shringarpure, Timothy Rolph, Andrew Cheng, Kitty Yale
Clinical Gastroenterology and Hepatology.2024;[Epub] CrossRef
Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: A 7-year retrospective cohort study of 3,380 adults using serial echocardiography
Gyuri Kim, Tae Yang Yu, Jae Hwan Jee, Ji Cheol Bae, Mira Kang, Jae Hyeon Kim
Diabetes & Metabolism.2024; 50(3): 101534. CrossRef
Anthropometry, laboratory, and PNPLA3 polymorphisms in a novel model for early identification and evaluation of nonalcoholic fatty liver disease
Amal A. Mohamed, Rania Al Dweik, Reem A. Abdelghafour, Ahmed Ramadan, Abbas M. Abbas, Hussein H. Samir, Nashwa M. Muharram, Randa Ibrahim Ahmed Elshiha, Naglaa El-Salawy, Doaa Ghaith, Marwa K. Darwish, Soha M. Abd El Salam, Eman A. Sultan, Amina S. Solima
Informatics in Medicine Unlocked.2024; 48: 101513. CrossRef
Relationship between fibrosis-4 score and microvascular complications in patients with type 2 diabetes mellitus
Beril Turan Erdogan, Abbas Ali Tam, Husniye Baser, Fatma Neslihan Cuhaci Seyrek, Sefika Burcak Polat, Reyhan Ersoy, Oya Topaloglu, Bekir Cakir
Arab Journal of Gastroenterology.2024; 25(3): 269. CrossRef
The relationship between muscle mass and fat content in body composition and non-alcoholic fatty liver disease in the Chinese general population: a cross-sectional study
Guoqiong Xu, Yuanyuan Wu, Jie Chen, Dan Xiang, Dongji Li
Frontiers in Medicine.2024;[Epub] CrossRef
Noninvasive Liver Fibrosis Indices as Indicators of Microvascular and Macrovascular Complications in Type 2 Diabetes
Hande Erman, Banu Boyuk, Seyma Arslan, Seydahmet Akin, Özcan Keskin
Metabolic Syndrome and Related Disorders.2024; 22(8): 619. CrossRef
Grading of Fatty Liver Based on Computed Tomography Hounsfield Unit Values versus Ultrasonography Grading
Sultan Abdulwadoud Alshoabi, Reyan Mohammed Alharbi, Rufaydah Bader Algohani, Shahad Abdullah Alahmadi, Maryam Ahmed, Samah F. Faqeeh, Dalal Alahmadi, Abdulaziz A. Qurashi, Fahad H. Alhazmi, Rakan Mohammed Alrehaili, Abdulrahman Khalil Almughathawi
Gastroenterology Insights.2024; 15(3): 588. CrossRef
Building in vitro models for mechanistic understanding of liver regeneration in chronic liver diseases
Khushi Karnawat, Rithika Parthasarathy, Mesevilhou Sakhrie, Harikeshav Karthik, Konatala Vibhuvan Krishna, Gowri Manohari Balachander
Journal of Materials Chemistry B.2024; 12(32): 7669. CrossRef
Autophagy alterations in obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease: the evidence from human studies
Patrycja Jakubek, Barbara Pakula, Martin Rossmeisl, Paolo Pinton, Alessandro Rimessi, Mariusz Roman Wieckowski
Internal and Emergency Medicine.2024; 19(5): 1473. CrossRef
Deploying a metabolic dysfunction-associated steatohepatitis consensus care pathway: findings from an educational pilot in three health systems
Sonal Kumar, Arpan Mohanty, Parvez Mantry, Robert E. Schwartz, Madeleine Haff, George Therapondos, Mazen Noureddin, Douglas Dieterich, Nigel Girgrah, Kristi Cohn, Mohanish Savanth, Michael Fuchs
BMC Primary Care.2024;[Epub] CrossRef
Efficacy and safety of dapagliflozin add‐on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled study
In‐Kyung Jeong, Kyung Mook Choi, Kyung Ah Han, Kyoung‐Ah Kim, In Joo Kim, Seung Jin Han, Won Young Lee, Soon Jib Yoo
Diabetes, Obesity and Metabolism.2024; 26(11): 5065. CrossRef
Plasma Adiponectin and Its Correlation with Carotid Intima-Media Thickness in Obesity and in Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Maha Hussein, Aasem Saif, Mona Amin, Osama Khalafallah, Ahmed Hussien, Samar Aboulsoud, Shrook Mousa, S. Razzaque Mohammed
Journal of Nutrition and Metabolism.2023; 2023: 1. CrossRef
Exposure to Bisphenol A, S, and F and its Association with Obesity and Diabetes Mellitus in General Adults of Korea: Korean National Environmental Health Survey (KoNEHS) 2015–2017
Min Kyong Moon, Min Joo Kim, Inae Lee, Sunmi Kim, Sohyeon Choi, Jeongim Park, Yoon Hee Cho, Sooyeon Hong, Jiyoung Yoo, Hyunwoong Park, Gi Jeong Cheon, Young Joo Park, Kyungho Choi
Exposure and Health.2023; 15(1): 53. CrossRef
Liver fat content assessed by conventional B-mode ultrasound and metabolic profile in non-diabetic patients: Implications for clinical practice
Rosanna Villani, Grazia Pia Magnati, Giulia Tuccari, Moris Sangineto, Antonino Davide Romano, Tommaso Cassano, Gaetano Serviddio
Ultrasound.2023; 31(3): 177. CrossRef
Association of cardiovascular health metrics with annual incidence of prediabetes or diabetes: Analysis of a nationwide real‐world database
Akira Okada, Hidehiro Kaneko, Satoshi Matsuoka, Hidetaka Itoh, Yuta Suzuki, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Satoko Yamaguchi, Koichi Node, Toshimasa Yamauchi, Hideo Yasunaga, Issei Komuro
Journal of Diabetes Investigation.2023; 14(3): 452. CrossRef
Effects of Environmental Cadmium Exposure on the Liver in Korean Adults: Cross-Sectional and Longitudinal Studies
Mi-Na Seo, Sang-Yong Eom, Ji-Ae Lim, Jung-Eum Lee, Byung-Sun Choi, Ho-Jang Kwon, Young-Seoub Hong, Heon Kim, Jung-Duck Park
Archives of Environmental Contamination and Toxicology.2023; 84(2): 237. CrossRef
Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes
Anika Bilal, Richard E. Pratley
Endocrinology and Metabolism Clinics of North America.2023; 52(2): 355. CrossRef
CD24 Gene Expression as a Risk Factor for Non-Alcoholic Fatty Liver Disease
Mona A. Amin, Halla M. Ragab, Nabila Abd El Maksoud, Wafaa Abd Elaziz
Diagnostics.2023; 13(5): 984. CrossRef
Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
Diabetes & Metabolism Journal.2023; 47(2): 220. CrossRef
Non-Alcoholic Fatty Liver Disease with Sarcopenia and Carotid Plaque Progression Risk in Patients with Type 2 Diabetes Mellitus
Yongin Cho, Hye-Sun Park, Byung Wook Huh, Yong-ho Lee, Seong Ha Seo, Da Hea Seo, Seong Hee Ahn, Seongbin Hong, So Hun Kim
Diabetes & Metabolism Journal.2023; 47(2): 232. CrossRef
Nonalcoholic fatty liver disease and type 2 diabetes: an observational and Mendelian randomization study
Yuetian Yu, Yuefeng Yu, Yuying Wang, Yi Chen, Ningjian Wang, Bin Wang, Yingli Lu
Frontiers in Endocrinology.2023;[Epub] CrossRef
β-sitosterol attenuates high- fat diet-induced hepatic steatosis in rats by modulating lipid metabolism, inflammation and ER stress pathway
Omayma AR Abo-Zaid, Fatma SM Moawed, Effet Soliman Ismail, Mostafa A. Farrag
BMC Pharmacology and Toxicology.2023;[Epub] CrossRef
Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017
Eugene Han, Kyung-Do Han, Yong-ho Lee, Kyung-Soo Kim, Sangmo Hong, Jung Hwan Park, Cheol-Young Park
Diabetes & Metabolism Journal.2023; 47(3): 347. CrossRef
Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
Metabolism.2023; 145: 155612. CrossRef
Role of vascular endothelial growth factor B in nonalcoholic fatty liver disease and its potential value
Yu-Qi Li, Lei Xin, Yu-Chi Zhao, Shang-Qi Li, Ya-Nuo Li
World Journal of Hepatology.2023; 15(6): 786. CrossRef
Increased risk of incident diabetes in patients with MAFLD not meeting the criteria for NAFLD
So Hee Park, Jiyun Park, So Yoon Kwon, You-Bin Lee, Gyuri Kim, Kyu Yeon Hur, Janghyun Koh, Jae Hwan Jee, Jae Hyeon Kim, Mira Kang, Sang-Man Jin
Scientific Reports.2023;[Epub] CrossRef
Significance of Diabetic Kidney Disease Biomarkers in Predicting Metabolic-Associated Fatty Liver Disease
Jaehyun Bae, Byung-Wan Lee
Biomedicines.2023; 11(7): 1928. CrossRef
An Evidence-Based Review of Diabetes Care: History, Types, Relationship to Cancer and Heart Disease, Co-Morbid Factors, and Preventive Measures
Umesh Chandra Gupta, Subhas Chandra Gupta, Shayle Sugandh Gupta
Current Nutrition & Food Science.2023; 19(4): 399. CrossRef
Associations of serum aminotransferase and the risk of all-cause and cause-specific mortality in Chinese type 2 diabetes: a community-based cohort study
Jian Su, Haoyu Guan, Xikang Fan, Hao Yu, Yu Qin, Jie Yang, Zheng Zhu, Chong Shen, Enchun Pan, Yan Lu, Jin-Yi Zhou, Ming Wu
BMJ Open.2023; 13(7): e068160. CrossRef
Retinoic acid signaling in fatty liver disease
Fathima N. Cassim Bawa, Yanqiao Zhang
Liver Research.2023; 7(3): 189. CrossRef
Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
Reeju Amatya, Donghee Lee, Kyoung Ah Min, Meong Cheol Shin
Pharmaceutics.2023; 15(7): 1963. CrossRef
Prevalence of Non-Alcoholic Fatty Liver Disease and Its Risk Factors in Korean Population
Sang Gyeong Lee, Songchan Oh, Moon Seong Kim, Jooyeon Kim, Eunjin Jung, Young Jun Kim, Jiyoun Hong
Food Supplements and Biomaterials for Health.2023;[Epub] CrossRef
Low‑dose ionizing radiation attenuates high glucose‑induced hepatic apoptosis and immune factor release via modulation of a miR‑155‑SOCS1 axis
Hongqiong Fan, Shanshan Liu, Benzheng Jiao, Xinyue Liang
Molecular Medicine Reports.2023;[Epub] CrossRef
CT-based measurement of visceral adipose tissue volume as a reliable tool for assessing metabolic risk factors in prediabetes across subtypes
Jihyun Kim, Keunyoung Kim
Scientific Reports.2023;[Epub] CrossRef
The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review
Teodora Biciusca, Sorina Ionelia Stan, Mara Amalia Balteanu, Ramona Cioboata, Alice Elena Ghenea, Suzana Danoiu, Ana-Maria Bumbea, Viorel Biciusca
Diagnostics.2023; 13(21): 3316. CrossRef
Circ_0004535/miR-1827/CASP8 network involved in type 2 diabetes mellitus with nonalcoholic fatty liver disease
Min Li, Ai Zeng, Xinle Tang, Hui Xu, Wei Xiong, Yanying Guo
Scientific Reports.2023;[Epub] CrossRef
Prevalence of High and Moderate Risk of Liver Fibrosis Among Patients With Diabetes at a Noncommunicable Diseases (NCD) Clinic in a Primary Healthcare Center in Northern India
Anubhav Mondal, Aninda Debnath, Ghurumourthy Dhandapani, Abhishek Sharma, Shveta Lukhmana, Geeta Yadav
Cureus.2023;[Epub] CrossRef
Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients
Mazhar Hussain, Muhammad Zafar Majeed Babar, Saba Tariq, Muhammad Irfan Ahmad, Lubna Akhtar
International Journal of Diabetes in Developing Countries.2022; 42(2): 290. CrossRef
Lead, mercury, and cadmium exposures are associated with obesity but not with diabetes mellitus: Korean National Environmental Health Survey (KoNEHS) 2015–2017
Min Kyong Moon, Inae Lee, Aram Lee, Hyunwoong Park, Min Joo Kim, Sunmi Kim, Yoon Hee Cho, Sooyeon Hong, Jiyoung Yoo, Gi Jeong Cheon, Kyungho Choi, Young Joo Park, Jeongim Park
Environmental Research.2022; 204: 111888. CrossRef
Association of Prenatal Famine Exposure With Inflammatory Markers and Its Impact on Adulthood Liver Function Across Consecutive Generations
Shiwei Yan, Jingqi Ruan, Yu Wang, Jiaxu Xu, Changhao Sun, Yucun Niu
Frontiers in Nutrition.2022;[Epub] CrossRef
Serum Metabolomics in Patients with Coexisting NAFLD and T2DM Using Liquid Chromatography-Mass Spectrometry
Cheng Hu, Xiaoyu Zhuang, Jiaqi Zhang, Tao Wang, Shengnan Du, Jinping Wang, Xuelian Peng, Qin Cao, Mingcai Zhang, Yuanye Jiang
Laboratory Medicine.2022; 53(4): 360. CrossRef
Genistein—Opportunities Related to an Interesting Molecule of Natural Origin
Ewa Garbiec, Judyta Cielecka-Piontek, Magdalena Kowalówka, Magdalena Hołubiec, Przemysław Zalewski
Molecules.2022; 27(3): 815. CrossRef
Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus
Hae Kyung Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
Diabetes & Metabolism Journal.2022; 46(1): 104. CrossRef
Long-term effects of the changes in hepatic steatosis status on the risk of incident type 2 diabetes mellitus: A 15-year community-based prospective cohort study
Seung Min Chung, Min Kyu Kang, Jinho Jung, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee, Rohit Loomba, Jung Gil Park, Jun Sung Moon
Diabetes Research and Clinical Practice.2022; 184: 109208. CrossRef
Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population‐Based Study in Germany
Yvonne Huber, Andreas Schulz, Irene Schmidtmann, Manfred Beutel, Norbert Pfeiffer, Thomas Münzel, Peter R. Galle, Philipp S. Wild, Karl J. Lackner, Jörn M. Schattenberg
Hepatology Communications.2022; 6(6): 1457. CrossRef
Non-alcoholic fatty liver disease
Rehab F. Abdel-Rahman
Asian Pacific Journal of Tropical Biomedicine.2022; 12(3): 99. CrossRef
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Yongin Cho, Yong-ho Lee
Endocrinology and Metabolism.2022; 37(1): 38. CrossRef
Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee
Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241. CrossRef
The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
Jiyun Park, Gyuri Kim, Bong-Sung Kim, Kyung-Do Han, So Yoon Kwon, So Hee Park, You-Bin Lee, Sang-Man Jin, Jae Hyeon Kim
Cardiovascular Diabetology.2022;[Epub] CrossRef
Sociodemographic and genetic determinants of nonalcoholic fatty liver disease in type 2 diabetes mellitus patients
Muhammad Adnan, Abdul Wajid, Wasif Noor, Andleeb Batool, Muhammad Aasim, Kamran Abbas, Quratul Ain
Journal of Genetic Engineering and Biotechnology.2022; 20(1): 68. CrossRef
Concordance between indirect fibrosis and steatosis indices and their predictors in subjects with overweight/obesity
Gaggini Melania, Vigna Luisella, Di Piazza Salvina, Gori Francesca, Tirelli Amedea Silvia, Bamonti Fabrizia, Maltinti Maristella, Napolitano Filomena, Chatzianagnostou Kyriazoula, Cristina Vassalle
Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity.2022; 27(7): 2617. CrossRef
Stéatopathie métabolique hépatique évaluée par le FibroScan® avec contrôle des paramètres d’atténuation (CAP) chez la personne diabétique de type 2 en Côte d’Ivoire
Jacko Abodo, Dimitri Kouamé, Jocelyne Danho, Moumouni Léilatou, Pierre Koffi-Dago, Adelaïde Hué, Assita Yao, Franck Kouassi, Anselme N’Guessan, Fulgence Bathaix
Médecine des Maladies Métaboliques.2022; 16(6): 550. CrossRef
Non-invasive diagnosis and staging of non-alcoholic fatty liver disease
Stergios Kechagias, Mattias Ekstedt, Christian Simonsson, Patrik Nasr
Hormones.2022; 21(3): 349. CrossRef
Association between organochlorine pesticides and nonalcoholic fatty liver disease in the National Health and Nutrition Examination Survey 2003–2004
Hyunji Sang, Kyu-Na Lee, Chang Hee Jung, Kyungdo Han, Eun Hee Koh
Scientific Reports.2022;[Epub] CrossRef
Increased Risk of NAFLD in Adults with Glomerular Hyperfiltration: An 8-Year Cohort Study Based on 147,162 Koreans
Dae-Jeong Koo, Mi Yeon Lee, Inha Jung, Sun Joon Moon, Hyemi Kwon, Eun-Jung Rhee, Cheol-Young Park, Won-Young Lee, Ki Won Oh, Se Eun Park
Journal of Personalized Medicine.2022; 12(7): 1142. CrossRef
Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Da Hea Seo, Young Ju Suh, Yongin Cho, Seong Hee Ahn, Seongha Seo, Seongbin Hong, Yong-ho Lee, Young Ju Choi, Eunjig Lee, So Hun Kim
Diabetes & Metabolism Journal.2022; 46(4): 630. CrossRef
New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis
Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai
Life.2022; 12(8): 1189. CrossRef
Efficacy and mechanism of Jiedu Tongluo Tiaogan Formula in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease: Study protocol for a parallel-armed, randomized controlled trial
Jinghan Xu, Chunli Piao, Yue Qu, Tianjiao Liu, Yuting Peng, Qi Li, Xiaohua Zhao, Pei Li, Xuemin Wu, Yawen Fan, Binqin Chen, Jie Yang
Frontiers in Pharmacology.2022;[Epub] CrossRef
Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes
Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai
Biomedicines.2022; 10(10): 2375. CrossRef
Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats
Yujie Zhong, Zhiman Li, Ruyi Jin, Yanpeng Yao, Silan He, Min Lei, Xin Wang, Chao Shi, Li Gao, Xiaoli Peng
Nutrients.2022; 14(23): 4994. CrossRef
The associations between changes in hepatic steatosis and heart failure and mortality: a nationwide cohort study
Jiyun Park, Gyuri Kim, Hasung Kim, Jungkuk Lee, Sang-Man Jin, Jae Hyeon Kim
Cardiovascular Diabetology.2022;[Epub] CrossRef
Association of Nonalcoholic Fatty Liver Disease with Coronary Artery Disease in Type 2 Diabetes Mellitus
Neelakandan Ramya, Golepu Karthikeya, Sethu Prabhu Shankar
Acta Medica International.2022; 9(1): 31. CrossRef
NAFLDin type 2 diabetes mellitus: Still many challenging questions
Simona Cernea, Itamar Raz
Diabetes/Metabolism Research and Reviews.2021;[Epub] CrossRef
The protective effect of shrimp cooked in different methods on high-cholesterol- induced fatty liver in rats
Nora A. AlFaris, Ghedeir M. Alshammari, Jozaa Z. AlTamimi, Lujain A. AlMousa, Nora M. AlKehayez, Dalal H. Aljabryn, Reham I. Alagal, Mohammed A. Yahya
Saudi Journal of Biological Sciences.2021; 28(1): 170. CrossRef
Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years
Hye Won Lee, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
Journal of Diabetes and its Complications.2021; 35(1): 107747. CrossRef
Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study
Keishi Ichikawa, Toru Miyoshi, Kazuhiro Osawa, Takashi Miki, Hironobu Toda, Kentaro Ejiri, Masatoki Yoshida, Yusuke Nanba, Masashi Yoshida, Kazufumi Nakamura, Hiroshi Morita, Hiroshi Ito
Cardiovascular Diabetology.2021;[Epub] CrossRef
Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study
Chileka Chiyanika, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Henry Lik-Yuen Chan, Steve C. N. Hui, David K. W. Yeung, Winnie C. W. Chu
Clinical and Translational Gastroenterology.2021; 12(2): e00300. CrossRef
Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
Sook Jung Lee, Byung-Wan Lee
The Journal of Korean Diabetes.2021; 22(1): 38. CrossRef
Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
Jingxuan Lian, Jianfang Fu
Frontiers in Endocrinology.2021;[Epub] CrossRef
Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway
In-Jin Cho, Da-Hee Oh, Jin Yoo, You-Cheol Hwang, Kyu Jeung Ahn, Ho-Yeon Chung, Soung Won Jeong, Ju-Young Moon, Sang-Ho Lee, Sung-Jig Lim, In-Kyung Jeong
Scientific Reports.2021;[Epub] CrossRef
Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?
Carolina M. Perdomo, Nuria Garcia-Fernandez, Javier Escalada
Journal of Clinical Medicine.2021; 10(9): 2040. CrossRef
Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy
Jin Yoo, In-Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung, You-Cheol Hwang
Metabolism.2021; 120: 154798. CrossRef
Association Between Thyroid Hormone Levels and Advanced Liver Fibrosis in Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease
Jing Du, Sanbao Chai, Xin Zhao, Jianbin Sun, Xiaomei Zhang, Lili Huo
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 2399. CrossRef
Association between toothbrushing and non-alcoholic fatty liver disease
Ji-Youn Kim, Yong-Moon Park, Gyu-Na Lee, Hyun Chul Song, Yu-Bae Ahn, Kyungdo Han, Seung-Hyun Ko, Houkai Li
PLOS ONE.2021; 16(5): e0243686. CrossRef
Non‐alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey
Joon Ho Moon, Bo Kyung Koo, Won Kim
Journal of Cachexia, Sarcopenia and Muscle.2021; 12(4): 964. CrossRef
Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Won Euh, Soo Lim, Jin-Wook Kim
Frontiers in Endocrinology.2021;[Epub] CrossRef
Modulation and bioinformatics screening of hepatic mRNA-lncRNAs (HML) network associated with insulin resistance in prediabetic and exercised mice
Fatemeh Kazeminasab, Sayed Mohammad Marandi, Maryam Baharlooie, Mohammad Hossein Nasr-Esfahani, Kamran Ghaedi
Nutrition & Metabolism.2021;[Epub] CrossRef
Liver Fibrosis Indices for the Prediction of Mortality in Korean Subjects: A 16-Year Prospective Cohort Study
Tae Jung Oh, Kyuho Kim, Jae Hoon Moon, Sung Hee Choi, Nam H Cho, Hak Chul Jang
Journal of the Endocrine Society.2021;[Epub] CrossRef
Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts
Jiwon Kim, Minyoung Lee, Soo Yeon Kim, Ji-Hye Kim, Ji Sun Nam, Sung Wan Chun, Se Eun Park, Kwang Joon Kim, Yong-ho Lee, Joo Young Nam, Eun Seok Kang
Endocrinology and Metabolism.2021; 36(4): 823. CrossRef
The association of hepatic steatosis and fibrosis with heart failure and mortality
Jiyun Park, Gyuri Kim, Hasung Kim, Jungkuk Lee, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim
Cardiovascular Diabetology.2021;[Epub] CrossRef
Magnetic Resonance-Based Assessments Better Capture Pathophysiologic Profiles and Progression in Nonalcoholic Fatty Liver Disease
Seung Joon Choi, Seong Min Kim, Yun Soo Kim, Oh Sang Kwon, Seung Kak Shin, Kyoung Kon Kim, Kiyoung Lee, Ie Byung Park, Cheol Soo Choi, Dong Hae Chung, Jaehun Jung, MunYoung Paek, Dae Ho Lee
Diabetes & Metabolism Journal.2021; 45(5): 739. CrossRef
Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
Eugene Han, Mi Kyung Kim, Byoung Kuk Jang, Hye Soon Kim
Diabetes & Metabolism Journal.2021; 45(5): 698. CrossRef
The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases
Hüseyin Vural, Ferah Armutcu, Omer Akyol, Ralf Weiskirchen
Clinica Chimica Acta.2021; 523: 374. CrossRef
Increased Visit-to-Visit Liver Enzyme Variability Is Associated with Incident Diabetes: A Community-Based 12-Year Prospective Cohort Study
Kyuhoon Bang, Ji Eun Jun, In-Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung, You-Cheol Hwang
Diabetes & Metabolism Journal.2021; 45(6): 890. CrossRef
Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
Frontiers in Endocrinology.2021;[Epub] CrossRef
Triglyceride Glucose-Waist Circumference Is Superior to the Homeostasis Model Assessment of Insulin Resistance in Identifying Nonalcoholic Fatty Liver Disease in Healthy Subjects
Hwi Seung Kim, Yun Kyung Cho, Eun Hee Kim, Min Jung Lee, Chang Hee Jung, Joong-Yeol Park, Hong-Kyu Kim, Woo Je Lee
Journal of Clinical Medicine.2021; 11(1): 41. CrossRef
The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study
Jung-Min Lee, Yong-Moon Park, Jae-Seung Yun, Yu-Bae Ahn, Kang-Moon Lee, Dae Bum Kim, Ji Min Lee, Kyungdo Han, Seung-Hyun Ko, Ming-Lung Yu
PLOS ONE.2020; 15(1): e0226351. CrossRef
Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study
Hyeok-Hee Lee, Yongin Cho, Young Ju Choi, Byung Wook Huh, Byung-Wan Lee, Eun Seok Kang, Seok Won Park, Bong-Soo Cha, Eun Jig Lee, Yong-ho Lee, Kap Bum Huh
Cardiovascular Diabetology.2020;[Epub] CrossRef
Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis
Chan-Hee Jung, Eun-Jung Rhee, Hyemi Kwon, Yoosoo Chang, Seungho Ryu, Won-Young Lee
Endocrinology and Metabolism.2020; 35(1): 165. CrossRef
Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study
Jun Hyung Kim, Jin Sil Moon, Seok Joon Byun, Jun Hyeok Lee, Dae Ryong Kang, Ki Chul Sung, Jang Young Kim, Ji Hye Huh
Cardiovascular Diabetology.2020;[Epub] CrossRef
Non-invasive diagnosis of nonalcoholic fatty liver disease: impact of age and other risk factors
Muharrem Bayrak
The Aging Male.2020; 23(5): 1275. CrossRef
Establishment of a Risk Prediction Model for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes
Yali Zhang, Rong Shi, Liang Yu, Liping Ji, Min Li, Fan Hu
Diabetes Therapy.2020; 11(9): 2057. CrossRef
Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
Dae Ho Lee
Endocrinology and Metabolism.2020; 35(2): 243. CrossRef
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee
Diabetes & Metabolism Journal.2020; 44(3): 382. CrossRef
Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes
D.H. Seo, Y.-h. Lee, S.W. Park, Y.J. Choi, B.W. Huh, E. Lee, K.B. Huh, S.H. Kim, B.-S. Cha
Diabetes & Metabolism.2020; 46(5): 362. CrossRef
Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin
Luana A. Biondo, Alexandre A. S. Teixeira, Karen C. de O. S. Ferreira, Jose C. R. Neto
Current Pharmaceutical Design.2020; 26(9): 932. CrossRef
Diabetes and Metabolism Journal in 2020: Good to Great
In-Kyung Jeong
Diabetes & Metabolism Journal.2020; 44(1): 1. CrossRef
Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis?
Soung Won Jeong
Clinical and Molecular Hepatology.2020; 26(2): 185. CrossRef
The sex-specific effects of blood lead, mercury, and cadmium levels on hepatic steatosis and fibrosis: Korean nationwide cross-sectional study
Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee
Journal of Trace Elements in Medicine and Biology.2020; 62: 126601. CrossRef
Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
Eugene Han, Yongin Cho, Kyung-won Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-wan Lee
Medicine.2020; 99(33): e21038. CrossRef
Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping
Zhipeng Liu, Yang Zhang, Sarah Graham, Xiaokun Wang, Defeng Cai, Menghao Huang, Roger Pique-Regi, Xiaocheng Charlie Dong, Y. Eugene Chen, Cristen Willer, Wanqing Liu
Journal of Hepatology.2020; 73(2): 263. CrossRef
Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Marieke de Vries, Jan Westerink, Karin H A H Kaasjager, Harold W de Valk
The Journal of Clinical Endocrinology & Metabolism.2020; 105(12): 3842. CrossRef
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung-Soo Kim, Byung-Wan Lee
Clinical and Molecular Hepatology.2020; 26(4): 430. CrossRef
Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
Eun-Jung Rhee
Endocrinology and Metabolism.2019; 34(3): 226. CrossRef
Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease
Anastasia Kontana, Konstantinos Tziomalos
World Journal of Gastroenterology.2019; 25(28): 3664. CrossRef

Clinical Diabetes & Therapeutics
Past and Current Status of Adult Type 2 Diabetes Mellitus Management in Korea: A National Health Insurance Service Database Analysis: Seung-Hyun Ko, Kyungdo Han, Yong-ho Lee, Junghyun Noh, Cheol-Young Park, Dae-Jung Kim, Chang Hee Jung, Ki-Up Lee, Kyung-Soo Ko; Diabetes Metab J. 2018;42(2):93-100. Published online April 19, 2018; DOI: https://doi.org/10.4093/dmj.2018.42.2.93

9,229 View
160 Download
84 Web of Science
85 Crossref

Abstract PDF PubReader

Korea's National Healthcare Program, the National Health Insurance Service (NHIS), a government-affiliated agency under the Korean Ministry of Health and Welfare, covers the entire Korean population. The NHIS supervises all medical services in Korea and establishes a systematic National Health Information database (DB). A health information DB system including all of the claims, medications, death information, and health check-ups, both in the general population and in patients with various diseases, is not common worldwide. On June 9, 2014, the NHIS signed a memorandum of understanding with the Korean Diabetes Association (KDA) to provide limited open access to its DB. By October 31, 2017, seven papers had been published through this collaborative research project. These studies were conducted to investigate the past and current status of type 2 diabetes mellitus and its complications and management in Korea. This review is a brief summary of the collaborative projects between the KDA and the NHIS over the last 3 years. According to the analysis, the national health check-up DB or claim DB were used, and the age category or study period were differentially applied.

Citations

Citations to this article as recorded by

Associations Between Physical Activity and the Risk of Hip Fracture Depending on Glycemic Status: A Nationwide Cohort Study
Kyoung Min Kim, Kyoung Jin Kim, Kyungdo Han, Yumie Rhee
The Journal of Clinical Endocrinology & Metabolism.2024; 109(3): e1194. CrossRef
Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study
Eun-Gyoung Hong, Kyung-Wan Min, Jung Soo Lim, Kyu-Jeung Ahn, Chul Woo Ahn, Jae-Myung Yu, Hye Soon Kim, Hyun Jin Kim, Won Kim, Dong Han Kim, Hak Chul Jang
Advances in Therapy.2024; 41(5): 1967. CrossRef
Gamma‐glutamyl transferase and the risk of all‐cause and disease‐specific mortality in patients with diabetes: A nationwide cohort study
Goh Eun Chung, Su‐Min Jeong, Su Jong Yu, Jeong‐Ju Yoo, Yuri Cho, Kyu‐na Lee, Dong Wook Shin, Yoon Jun Kim, Jung‐Hwan Yoon, Kyungdo Han, Eun Ju Cho
Journal of Diabetes.2024;[Epub] CrossRef
2023 Diabetic Kidney Disease Fact Sheet in Korea
Nam Hoon Kim, Mi-Hae Seo, Jin Hyung Jung, Kyung Do Han, Mi Kyung Kim, Nan Hee Kim
Diabetes & Metabolism Journal.2024; 48(3): 463. CrossRef
Effect of smoking on the risk of gastrointestinal cancer after cholecystectomy: A national population-based cohort study
Minseob Kim, Kyung-Do Han, Seung-Hyun Ko, Yoonkyung Woo, Jae Hyun Han
World Journal of Gastrointestinal Surgery.2024; 16(9): 2796. CrossRef
Association Between Glycemic Status and the Risk of Kidney Cancer in Men and Women: A Nationwide Cohort Study
Joo-Hyun Park, Jung Yong Hong, Kyungdo Han, Jay J. Shen
Diabetes Care.2023; 46(1): 38. CrossRef
Remnant Cholesterol Is an Independent Predictor of Type 2 Diabetes: A Nationwide Population-Based Cohort Study
Ji Hye Huh, Eun Roh, Seong Jin Lee, Sung-Hee Ihm, Kyung-Do Han, Jun Goo Kang
Diabetes Care.2023; 46(2): 305. CrossRef
Efficacy of acupuncture on cardiovascular complications in patients with diabetes mellitus in Korea: A nationwide retrospective cohort
Hyejin Jung, Tiana Won, Ga-Yeon Kim, Jowon Jang, Sujung Yeo, Sabina Lim
Journal of Integrative Medicine.2023; 21(2): 176. CrossRef
Comparison of Operational Definition of Type 2 Diabetes Mellitus Based on Data from Korean National Health Insurance Service and Korea National Health and Nutrition Examination Survey
Jong Ha Baek, Yong-Moon Park, Kyung Do Han, Min Kyong Moon, Jong Han Choi, Seung-Hyun Ko
Diabetes & Metabolism Journal.2023; 47(2): 201. CrossRef
Epidemiology of PAH in Korea: An Analysis of the National Health Insurance Data, 2002–2018
Albert Youngwoo Jang, Hyeok-Hee Lee, Hokyou Lee, Hyeon Chang Kim, Wook-Jin Chung
Korean Circulation Journal.2023; 53(5): 313. CrossRef
Increased Risks of Open-Angle Glaucoma in Untreated Hypertension
Jihei Sara Lee, Yong Joon Kim, Sunyeup Kim, Hyoung Won Bae, Sung Soo Kim, Seung Won Lee, Chan Yun Kim
American Journal of Ophthalmology.2023; 252: 111. CrossRef
Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim
Cardiovascular Diabetology.2023;[Epub] CrossRef
Association between glycemic status and the risk of acute pancreatitis: a nationwide population-based study
In Rae Cho, Kyung-Do Han, Sang Hyub Lee, Young Hoon Choi, Kwang Hyun Chung, Jin Ho Choi, Namyoung Park, Min Woo Lee, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim
Diabetology & Metabolic Syndrome.2023;[Epub] CrossRef
Type 2 Diabetes and Its Association With Psychiatric Disorders in Young Adults in South Korea
Min-Kyung Lee, Su-Young Lee, Seo-Young Sohn, Jiyeon Ahn, Kyungdo Han, Jae-Hyuk Lee
JAMA Network Open.2023; 6(6): e2319132. CrossRef
Cholecystectomy Increases the Risk of Type 2 Diabetes in the Korean Population
Ji Hye Huh, Kyong Joo Lee, Yun Kyung Cho, Shinje Moon, Yoon Jung Kim, Eun Roh, Kyung-do Han, Dong Hee Koh, Jun Goo Kang, Seong Jin Lee, Sung-Hee Ihm
Annals of Surgery.2023; 278(2): e264. CrossRef
The Risk of Type 2 Diabetes Mellitus according to Changes in Obesity Status in Late Middle-Aged Adults: A Nationwide Cohort Study of Korea
Joon Ho Moon, Yeonhoon Jang, Tae Jung Oh, Se Young Jung
Diabetes & Metabolism Journal.2023; 47(4): 514. CrossRef
Scalable Infrastructure Supporting Reproducible Nationwide Healthcare Data Analysis toward FAIR Stewardship
Ji-Woo Kim, Chungsoo Kim, Kyoung-Hoon Kim, Yujin Lee, Dong Han Yu, Jeongwon Yun, Hyeran Baek, Rae Woong Park, Seng Chan You
Scientific Data.2023;[Epub] CrossRef
Association between Smoking Status and the Risk of Hip Fracture in Patients with Type 2 Diabetes: A Nationwide Population-Based Study
Se-Won Lee, Jun-Young Heu, Ju-Yeong Kim, Jinyoung Kim, Kyungdo Han, Hyuk-Sang Kwon
Endocrinology and Metabolism.2023; 38(6): 679. CrossRef
Urgensi Kepesertaan BPJS Kesehatan Sebagai Syarat Peralihan Hak Atas Tanah Berdasarkan Instruksi Presiden Nomor 1 Tahun 2022 Tentang Optimalisasi Pelaksanaan Program Jaminan Kesehatan Nasional
Nur Dwi Safitri, Fauziyah Fauziyah
Indonesian Journal of Law and Justice.2023; 1(2): 10. CrossRef
Risk of Incident Dementia According to Glycemic Status and Comorbidities of Hyperglycemia: A Nationwide Population-Based Cohort Study
Woo Jung Kim, Seo Jung Lee, Eun Lee, Eun Y. Lee, Kyungdo Han
Diabetes Care.2022; 45(1): 134. CrossRef
Effects of physical activity on cardiovascular outcomes and mortality in Korean patients with diabetes: a nationwide population-based cohort study
Inha Jung, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee
Cardiovascular Prevention and Pharmacotherapy.2022; 4(1): 42. CrossRef
Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
Sangmo Hong, Chang Hee Jung, Song Han, Cheol-Young Park
Diabetes & Metabolism Journal.2022; 46(1): 63. CrossRef
Changes in Patterns of Physical Activity and Risk of Heart Failure in Newly Diagnosed Diabetes Mellitus Patients
Inha Jung, Hyemi Kwon, Se Eun Park, Kyung-Do Han, Yong-Gyu Park, Eun-Jung Rhee, Won-Young Lee
Diabetes & Metabolism Journal.2022; 46(2): 327. CrossRef
Synergistic association between underweight and type 2 diabetes on the development of laryngeal cancer: a national population-based retrospective cohort study
Oh. Hyeong Lee, Yong-Moon Park, Seung-Hyun Ko, Kyuna Lee, Yeonji Kim, Kyungdo Han, Jung-Hae Cho
BMC Cancer.2022;[Epub] CrossRef
Cardiovascular Implications of the 2021 KDIGO Blood Pressure Guideline for Adults With Chronic Kidney Disease
Hyeok-Hee Lee, Hokyou Lee, Raymond R. Townsend, Dong-Wook Kim, Sungha Park, Hyeon Chang Kim
Journal of the American College of Cardiology.2022; 79(17): 1675. CrossRef
Cumulative Exposure to High γ-Glutamyl Transferase Level and Risk of Diabetes: A Nationwide Population-Based Study
Ji-Yeon Park, Kyungdo Han, Hun-Sung Kim, Jae-Hyoung Cho, Kun-Ho Yoon, Mee Kyoung Kim, Seung-Hwan Lee
Endocrinology and Metabolism.2022; 37(2): 272. CrossRef
Skin accumulation of advanced glycation end products and cardiovascular risk in Korean patients with type 2 diabetes mellitus
Lee-Seoul Choi, Kainat Ahmed, Young-Seol Kim, Jung-Eun Yim
Heliyon.2022; 8(6): e09571. CrossRef
Risk for Behçet’s disease gauged via high-density lipoprotein cholesterol: a nationwide population-based study in Korea
Yeong Ho Kim, Hyun Jee Kim, Jin Woo Park, Kyung Do Han, Yong Gyu Park, Young Bok Lee, Ji Hyun Lee
Scientific Reports.2022;[Epub] CrossRef
Association between the Diabetes Drug Cost and Cardiovascular Events and Death in Korea: A National Health Insurance Service Database Analysis
Seung Min Chung, Ji-In Lee, Eugene Han, Hyun-Ae Seo, Eonju Jeon, Hye Soon Kim, Ji Sung Yoon
Endocrinology and Metabolism.2022; 37(5): 759. CrossRef
Remnant cholesterol and the risk of cardiovascular disease in type 2 diabetes: a nationwide longitudinal cohort study
Ji Hye Huh, Kyung-do Han, Yun Kyung Cho, Eun Roh, Jun Goo Kang, Seong Jin Lee, Sung-Hee Ihm
Cardiovascular Diabetology.2022;[Epub] CrossRef
Associations between migraine and major cardiovascular events in type 2 diabetes mellitus
Dae Young Cheon, Kyungdo Han, Ye Seul Yang, Yerim Kim, Sang-Hwa Lee, Chulho Kim, Jong-Hee Sohn, Mi Sun Oh, Byung-Chul Lee, Minwoo Lee, Kyung-Ho Yu
Cardiovascular Diabetology.2022;[Epub] CrossRef
Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study
Jun Sung Moon, Sunghwan Suh, Sang Soo Kim, Heung Yong Jin, Jeong Mi Kim, Min Hee Jang, Kyung Ae Lee, Ju Hyung Lee, Seung Min Chung, Young Sang Lyu, Jin Hwa Kim, Sang Yong Kim, Jung Eun Jang, Tae Nyun Kim, Sung Woo Kim, Eonju Jeon, Nan Hee Cho, Mi-Kyung Ki
Diabetes & Metabolism Journal.2021; 45(5): 675. CrossRef
Umbilical Cord-Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 Cell
Kyung-Soo Kim, Yeon Kyung Choi, Mi Jin Kim, Jung Wook Hwang, Kyunghoon Min, Sang Youn Jung, Soo-Kyung Kim, Yong-Soo Choi, Yong-Wook Cho
Diabetes & Metabolism Journal.2021; 45(2): 260. CrossRef
Associations of general obesity and central obesity with the risk of hepatocellular carcinoma in a Korean population: A national population‐based cohort study
Seawon Hwang, Yong‐Moon Park, Kyung‐Do Han, Jae‐Seung Yun, Seung‐Hyun Ko, Yu‐Bae Ahn, Jae Hyun Han
International Journal of Cancer.2021; 148(5): 1144. CrossRef
Glycaemic control with add‐on thiazolidinedione or a sodium‐glucose co‐transporter‐2 inhibitor in patients with type 2 diabetes after the failure of an oral triple antidiabetic regimen: A 24‐week, randomized controlled trial
Jaehyun Bae, Ji Hye Huh, Minyoung Lee, Yong‐Ho Lee, Byung‐Wan Lee
Diabetes, Obesity and Metabolism.2021; 23(2): 609. CrossRef
Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study
Hokyou Lee, Yong-ho Lee, Seung Up Kim, Hyeon Chang Kim
Clinical Gastroenterology and Hepatology.2021; 19(10): 2138. CrossRef
Severe hypoglycemia as a preventable risk factor for cardiovascular disease in patients with type 2 diabetes mellitus
Soo-Yeon Choi, Seung-Hyun Ko
The Korean Journal of Internal Medicine.2021; 36(2): 263. CrossRef
Changes in metabolic syndrome status affect the incidence of end-stage renal disease in the general population: a nationwide cohort study
Eun Sil Koh, Kyung Do Han, Mee Kyoung Kim, Eun Sook Kim, Min-Kyung Lee, Ga Eun Nam, Oak-Kee Hong, Hyuk-Sang Kwon
Scientific Reports.2021;[Epub] CrossRef
Status of Diabetic Neuropathy in Korea: A National Health Insurance Service-National Sample Cohort Analysis (2006 to 2015)
Seong-Su Moon, Chong Hwa Kim, Seon Mee Kang, Eun Sook Kim, Tae Jung Oh, Jae-Seung Yun, Ho Chan Cho, Dae Jung Kim, Tae Sun Park
Diabetes & Metabolism Journal.2021; 45(1): 115. CrossRef
Thirty-six Year Trends in Mortality from Diseases of Circulatory System in Korea
Jongmin Baek, Hokyou Lee, Hyeok-Hee Lee, Ji Eun Heo, So Mi Jemma Cho, Hyeon Chang Kim
Korean Circulation Journal.2021; 51(4): 320. CrossRef
Severe hypoglycemia and the risk of end stage renal disease in type 2 diabetes
Jae-Seung Yun, Yong-Moon Park, Kyungdo Han, Hyung-Wook Kim, Seon-Ah Cha, Yu-Bae Ahn, Seung-Hyun Ko
Scientific Reports.2021;[Epub] CrossRef
Adherence to Antihypertensive Medication and Incident Cardiovascular Events in Young Adults With Hypertension
Hokyou Lee, Yuichiro Yano, So Mi Jemma Cho, Ji Eun Heo, Dong-Wook Kim, Sungha Park, Donald M. Lloyd-Jones, Hyeon Chang Kim
Hypertension.2021; 77(4): 1341. CrossRef
Cumulative exposure to impaired fasting glucose and future risk of type 2 diabetes mellitus
Mee Kyoung Kim, Kyungdo Han, Eun Sil Koh, Oak-Kee Hong, Ki-Hyun Baek, Ki-Ho Song, Hyuk-Sang Kwon
Diabetes Research and Clinical Practice.2021; 175: 108799. CrossRef
Association between toothbrushing and non-alcoholic fatty liver disease
Ji-Youn Kim, Yong-Moon Park, Gyu-Na Lee, Hyun Chul Song, Yu-Bae Ahn, Kyungdo Han, Seung-Hyun Ko, Houkai Li
PLOS ONE.2021; 16(5): e0243686. CrossRef
Weight change and microvascular outcomes in patients with new-onset diabetes: a nationwide cohort study
Eun Sil Koh, Kyung Do Han, Mee Kyoung Kim, Eun Sook Kim, Min-Kyung Lee, Ga Eun Nam, Hyuk-Sang Kwon
The Korean Journal of Internal Medicine.2021; 36(4): 932. CrossRef
Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future
Brian Godman, Mainul Haque, Santosh Kumar, Salequl Islam, Jaykaran Charan, Farhana Akter, Amanj Kurdi, Eleonora Allocati, Muhammed Abu Bakar, Sagir Abdur Rahim, Nusrat Sultana, Farzana Deeba, M. A. Halim Khan, A. B. M Muksudul Alam, Iffat Jahan, Zubair Ma
Current Medical Research and Opinion.2021; 37(9): 1529. CrossRef
Development and Validation of a Deep Learning Based Diabetes Prediction System Using a Nationwide Population-Based Cohort
Sang Youl Rhee, Ji Min Sung, Sunhee Kim, In-Jeong Cho, Sang-Eun Lee, Hyuk-Jae Chang
Diabetes & Metabolism Journal.2021; 45(4): 515. CrossRef
Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
Ja Young Jeon, Kyoung Hwa Ha, Dae Jung Kim
Diabetes & Metabolism Journal.2021; 45(4): 505. CrossRef
Nonalcoholic fatty liver disease and the risk of insulin-requiring gestational diabetes
Sang Youn You, Kyungdo Han, Seung-Hawn Lee, Mee Kyoung Kim
Diabetology & Metabolic Syndrome.2021;[Epub] CrossRef
On-Treatment Blood Pressure and Cardiovascular Outcomes in Adults With Hypertension and Left Ventricular Hypertrophy
Hyeok-Hee Lee, Hokyou Lee, So Mi Jemma Cho, Dong-Wook Kim, Sungha Park, Hyeon Chang Kim
Journal of the American College of Cardiology.2021; 78(15): 1485. CrossRef
The Effects of Glucose Lowering Agents on the Secondary Prevention of Coronary Artery Disease in Patients with Type 2 Diabetes
Inha Jung, Hyemi Kwon, Se Eun Park, Kyung-Do Han, Yong-Gyu Park, Eun-Jung Rhee, Won-Young Lee
Endocrinology and Metabolism.2021; 36(5): 977. CrossRef
Changes in metabolic syndrome and its components and the risk of type 2 diabetes: a nationwide cohort study
Min-Kyung Lee, Kyungdo Han, Mee Kyoung Kim, Eun Sil Koh, Eun Sook Kim, Ga Eun Nam, Hyuk-Sang Kwon
Scientific Reports.2020;[Epub] CrossRef
Obesity and metabolic health status are determinants for the clinical expression of hypertrophic cardiomyopathy
Jun-Bean Park, Da Hye Kim, Heesun Lee, In-Chang Hwang, Yeonyee E Yoon, Hyo Eun Park, Su-Yeon Choi, Yong-Jin Kim, Goo-Yeong Cho, Kyungdo Han, Steve R Ommen, Hyung-Kwan Kim
European Journal of Preventive Cardiology.2020; 27(17): 1849. CrossRef
Clinical Characteristics and Prevalence of Comorbidities according to Metformin Use in Korean Patients with Type 2 Diabetes
Sang Ouk Chin, In Gyoon Ha, Sang Youl Rhee, Su Jin Jeong, Suk Chon, Sung Hoon Kim, Kyu Jeung Ahn, Sei Hyun Baik, Yongsoo Park, Moon Suk Nam, Kwan Woo Lee, Jeong Taek Woo
International Journal of Endocrinology.2020; 2020: 1. CrossRef
Impact of Mean and Variability of High‐Density Lipoprotein‐Cholesterol on the Risk of Myocardial Infarction, Stroke, and Mortality in the General Population
Byung‐Hun Han, Kyungdo Han, Kun‐Ho Yoon, Mee Kyoung Kim, Seung‐Hwan Lee
Journal of the American Heart Association.2020;[Epub] CrossRef
The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study
Jung-Min Lee, Yong-Moon Park, Jae-Seung Yun, Yu-Bae Ahn, Kang-Moon Lee, Dae Bum Kim, Ji Min Lee, Kyungdo Han, Seung-Hyun Ko, Ming-Lung Yu
PLOS ONE.2020; 15(1): e0226351. CrossRef
Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study
Sangmo Hong, Kyungdo Han, Cheol-Young Park
Mayo Clinic Proceedings.2020; 95(1): 101. CrossRef
Association Between Glycemic Status and the Risk of Parkinson Disease: A Nationwide Population-Based Study
Sang Youl Rhee, Kyung-Do Han, Hyemi Kwon, Se-Eun Park, Yong-Gyu Park, Yang-Hyun Kim, Soon-Jip Yoo, Eun-Jung Rhee, Won-Young Lee
Diabetes Care.2020; 43(9): 2169. CrossRef
A model to predict risk of stroke in middle-aged adults with type 2 diabetes generated from a nationwide population-based cohort study in Korea
Mee-Kyoung Kim, Kyungdo Han, Jae-Hyoung Cho, Hyuk-Sang Kwon, Kun-Ho Yoon, Seung-Hwan Lee
Diabetes Research and Clinical Practice.2020; 163: 108157. CrossRef
Diabetic Retinopathy and Related Clinical Practice for People with Diabetes in Korea: A 10-Year Trend Analysis
Yoo-Ri Chung, Kyoung Hwa Ha, Kihwang Lee, Dae Jung Kim
Diabetes & Metabolism Journal.2020; 44(6): 928. CrossRef
Prepregnancy smoking and the risk of gestational diabetes requiring insulin therapy
Mee Kyoung Kim, Kyungdo Han, Sang Youn You, Hyuk-Sang Kwon, Kun-Ho Yoon, Seung-Hwan Lee
Scientific Reports.2020;[Epub] CrossRef
Cardiovascular Risk of Isolated Systolic or Diastolic Hypertension in Young Adults
Hokyou Lee, Yuichiro Yano, So Mi Jemma Cho, Jong Heon Park, Sungha Park, Donald M. Lloyd-Jones, Hyeon Chang Kim
Circulation.2020; 141(22): 1778. CrossRef
Middle-aged men with type 2 diabetes as potential candidates for pancreatic cancer screening: a 10-year nationwide population-based cohort study
Dong-Hoe Koo, Kyung-Do Han, Hong Joo Kim, Cheol-Young Park
Acta Diabetologica.2020; 57(2): 197. CrossRef
Predicting the Development of Myocardial Infarction in Middle-Aged Adults with Type 2 Diabetes: A Risk Model Generated from a Nationwide Population-Based Cohort Study in Korea
Seung-Hwan Lee, Kyungdo Han, Hun-Sung Kim, Jae-Hyoung Cho, Kun-Ho Yoon, Mee Kyoung Kim
Endocrinology and Metabolism.2020; 35(3): 636. CrossRef
Fasting plasma glucose level and the risk of open angle glaucoma: Nationwide population-based cohort study in Korea
Jin A. Choi, Yong-Moon Park, Kyungdo Han, Jiyoung Lee, Jae-Seung Yun, Seung-Hyun Ko, Bang V Bui
PLOS ONE.2020; 15(9): e0239529. CrossRef
Effect of Variability in Blood Pressure, Glucose and Cholesterol Concentrations, and Body Weight on Emergency Hospitalization and 30‐Day Mortality in the General Population
Seung‐Hwan Lee, Kyungdo Han, Hyuk‐Sang Kwon, Kun‐Ho Yoon, Mee Kyoung Kim
Journal of the American Heart Association.2020;[Epub] CrossRef
Does Diabetes Increase the Risk of Contracting COVID-19? A Population-Based Study in Korea
Sung-Youn Chun, Dong Wook Kim, Sang Ah Lee, Su Jung Lee, Jung Hyun Chang, Yoon Jung Choi, Seong Woo Kim, Sun Ok Song
Diabetes & Metabolism Journal.2020; 44(6): 897. CrossRef
Appropriate Medical Technology in the Era of the 4th Industrial Revolution
Sang Youl Rhee
The Korean Journal of Medicine.2019; 94(5): 387. CrossRef
Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study
Su Jin Lee, Kyoung Hwa Ha, Jung Hyun Lee, Hokyou Lee, Dae Jung Kim, Hyeon Chang Kim, Tatsuo Shimosawa
PLOS ONE.2019; 14(2): e0211959. CrossRef
2017 ACC/AHA Blood Pressure Classification and Cardiovascular Disease in 15 Million Adults of Age 20–94 Years
Hokyou Lee, So Mi Jemma Cho, Jong Heon Park, Sungha Park, Hyeon Chang Kim
Journal of Clinical Medicine.2019; 8(11): 1832. CrossRef
Management of Cardiovascular Risk Factors in Elderly Diabetes Mellitus Patients
Sung Hoon Yu
The Journal of Korean Diabetes.2019; 20(4): 233. CrossRef
Cholesterol levels and development of cardiovascular disease in Koreans with type 2 diabetes mellitus and without pre-existing cardiovascular disease
Mee Kyoung Kim, Kyungdo Han, Han Na Joung, Ki-Hyun Baek, Ki-Ho Song, Hyuk-Sang Kwon
Cardiovascular Diabetology.2019;[Epub] CrossRef
Comprehensive Efforts Are Needed to Improve the Quality of Primary Diabetes Care in Korea
Chan-Hee Jung
Endocrinology and Metabolism.2019; 34(3): 265. CrossRef
Blood Pressure and Development of Cardiovascular Disease in Koreans With Type 2 Diabetes Mellitus
Mee Kyoung Kim, Kyungdo Han, Eun Sil Koh, Eun Sook Kim, Min-Kyung Lee, Ga Eun Nam, Hyuk-Sang Kwon
Hypertension.2019; 73(2): 319. CrossRef
Weight change and mortality and cardiovascular outcomes in patients with new-onset diabetes mellitus: a nationwide cohort study
Mee Kyoung Kim, Kyungdo Han, Eun Sil Koh, Eun Sook Kim, Min-Kyung Lee, Ga Eun Nam, Hyuk-Sang Kwon
Cardiovascular Diabetology.2019;[Epub] CrossRef
Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2019;43:582–9)
Tae Seo Sohn
Diabetes & Metabolism Journal.2019; 43(6): 909. CrossRef
Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study
Yoo-Ri Chung, Kyoung Hwa Ha, Hyeon Chang Kim, Sang Jun Park, Kihwang Lee, Dae Jung Kim
Diabetes & Metabolism Journal.2019; 43(5): 640. CrossRef
The Need to Improve the Quality of Diabetes Care in Korea
Seung Jin Han, Dae Jung Kim
Journal of Korean Medical Science.2019;[Epub] CrossRef
Chasms in Achievement of Recommended Diabetes Care among Geographic Regions in Korea
Sanghyun Cho, Ji-Yeon Shin, Hyun Joo Kim, Sang Jun Eun, Sungchan Kang, Won Mo Jang, Hyemin Jung, Yoon Kim, Jin Yong Lee
Journal of Korean Medical Science.2019;[Epub] CrossRef
An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?
Ji A Seo
Diabetes & Metabolism Journal.2019; 43(5): 578. CrossRef
National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus
Jisu Kim, Susin Park, Hyunsoo Kim, Nam Kyung Je
European Journal of Clinical Pharmacology.2019; 75(12): 1723. CrossRef
HDL-Cholesterol, Its Variability, and the Risk of Diabetes: A Nationwide Population-Based Study
Seung-Hwan Lee, Hun-Sung Kim, Yong-Moon Park, Hyuk-Sang Kwon, Kun-Ho Yoon, Kyungdo Han, Mee Kyoung Kim
The Journal of Clinical Endocrinology & Metabolism.2019; 104(11): 5633. CrossRef
Current Management of Type 2 Diabetes Mellitus in Primary Care Clinics in Korea
Da Hea Seo, Shinae Kang, Yong-ho Lee, Jung Yoon Ha, Jong Suk Park, Byoung-Wan Lee, Eun Seok Kang, Chul Woo Ahn, Bong-Soo Cha
Endocrinology and Metabolism.2019; 34(3): 282. CrossRef
Heritability estimation of dichotomous phenotypes using a liability threshold model on ascertained family‐based samples
Wonji Kim, Soo Heon Kwak, Sungho Won
Genetic Epidemiology.2019; 43(7): 761. CrossRef
Letter: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
Jun Sung Moon
Diabetes & Metabolism Journal.2019; 43(6): 911. CrossRef

Clinical Care/Education
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus: Sung-Ho Kim, Jung-Hwa Yoo, Woo Je Lee, Cheol-Young Park; Diabetes Metab J. 2016;40(5):339-353. Published online September 12, 2016; DOI: https://doi.org/10.4093/dmj.2016.40.5.339

7,397 View
189 Download
46 Web of Science
43 Crossref

Abstract PDF PubReader

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral antidiabetic agent for the treatment of type 2 diabetes mellitus. They increase endogenous levels of incretin hormones, which stimulate glucose-dependent insulin secretion, decrease glucagon secretion, and contribute to reducing postprandial hyperglycemia. Although DPP-4 inhibitors have similar benefits, they can be differentiated in terms of their chemical structure, pharmacology, efficacy and safety profiles, and clinical considerations. Gemigliptin (brand name: Zemiglo), developed by LG Life Sciences, is a potent, selective, competitive, and long acting DPP-4 inhibitor. Various studies have shown that gemigliptin is an optimized DPP-4 inhibitor in terms of efficacy, safety, and patient compliance for treatment of type 2 diabetes mellitus. In this review, we summarize the characteristics of gemigliptin and discuss its potential benefits in clinical practice.

Citations

Citations to this article as recorded by

A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inh
Hae Jin Kim, Jung Hyun Noh, Min Kyong Moon, Sung Hee Choi, Seung-Hyun Ko, Eun-Jung Rhee, Kyu Yeon Hur, In-Kyung Jeong, Mark Yorek
Journal of Diabetes Research.2024; 2024: 1. CrossRef
Gemigliptin, a potent selective dipeptidyl peptidase 4 inhibitor, protects endothelial progenitor cells by oxidative stress via caspase-3 dependent pathway
Mijung Lee, Amna Rashid Tariq, Manho Kim
Biochemistry and Biophysics Reports.2024; 38: 101673. CrossRef
Selective targeting of dipeptidyl‐peptidase 4 (DPP‐4) positive senescent chondrocyte ameliorates osteoarthritis progression
Du Hyun Ro, Gun Hee Cho, Ji Yoon Kim, Seong Ki Min, Ha Ru Yang, Hee Jung Park, Sun Young Wang, You Jung Kim, Myung Chul Lee, Hyun Cheol Bae, Hyuk‐Soo Han
Aging Cell.2024;[Epub] CrossRef
Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM)
Dong-Wei Shao, Li-Jie Zhao, Jin-Feng Sun
European Journal of Medicinal Chemistry.2024; 272: 116464. CrossRef
Financial Benefits of Renal Dose-Adjusted Dipeptidyl Peptidase-4 Inhibitors for Patients with Type 2 Diabetes and Chronic Kidney Disease
Hun Jee Choe, Yeh-Hee Ko, Sun Joon Moon, Chang Ho Ahn, Kyoung Hwa Ha, Hyeongsuk Lee, Jae Hyun Bae, Hyung Joon Joo, Hyejin Lee, Jang Wook Son, Dae Jung Kim, Sin Gon Kim, Kwangsoo Kim, Young Min Cho
Endocrinology and Metabolism.2024; 39(4): 622. CrossRef
Efficient integration of analytical quality-by-design and tri-hued HPLC-DAD approach for synchronized assessment of gemigliptin and rosuvastatin in their fixed-dose pills: Application to stability study
Sara M. Mohyeldin, Hoda G. Daabees, Wael Talaat, Miranda F. Kamal
Sustainable Chemistry and Pharmacy.2024; 42: 101777. CrossRef
Opportunities and challenges of incretin-based hypoglycemic agents treating type 2 diabetes mellitus from the perspective of physiological disposition
Yaochen Xie, Qian Zhou, Qiaojun He, Xiaoyi Wang, Jincheng Wang
Acta Pharmaceutica Sinica B.2023; 13(6): 2383. CrossRef
Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study
Sang-Yong Kim, Sungrae Kim
Diabetes Therapy.2023; 14(1): 109. CrossRef
Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium–glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults
Sae Im Jeong, Yun Kim, Jae Jin Nah, Wan Huh, In‐Jin Jang, Jun Gi Hwang, SeungHwan Lee
British Journal of Clinical Pharmacology.2023; 89(6): 1780. CrossRef
1,2,3‐Triazole analogs with bulky and conformationally rigid substructures: Synthesis and in vitro evaluation as DPP‐4 inhibitors
Duy‐Viet Vo, Jongkook Lee, Haeil Park
Bulletin of the Korean Chemical Society.2023; 44(5): 425. CrossRef
DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
Kunika Saini, Smriti Sharma, Yousuf Khan
Frontiers in Molecular Biosciences.2023;[Epub] CrossRef
The effect of gemigliptin treatment on immune parameters including regulatory T cells in patients with type 2 diabetes and moderate to very severe chronic renal impairment
Yanghyeon Kim, Nagyeom Lee, Sujung Heo, Ye Na Kim, Ho Sik Shin, Yeonsoon Jung, Hark Rim
Medicine.2023; 102(49): e36455. CrossRef
Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
Sangmo Hong, Chang Hee Jung, Song Han, Cheol-Young Park
Diabetes & Metabolism Journal.2022; 46(1): 63. CrossRef
Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?
Petr Busek, Jonathan S. Duke-Cohan, Aleksi Sedo
Cancers.2022; 14(9): 2072. CrossRef
Divergent Reaction of Activated Pyridines with α,α-Difluorinated gem-Diols: Regioselective Synthesis of gem-Difluorinated Dihydropyridines and Dihydropyridones
Koushik Patra, Mallu Kesava Reddy, Sumitava Mallik, Mahiuddin Baidya
Organic Letters.2022; 24(22): 4014. CrossRef
Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression
Kyeong-Min Lee, Yeo Jin Hwang, Gwon-Soo Jung
Biochemical and Biophysical Research Communications.2022; 626: 135. CrossRef
FDA-Approved Trifluoromethyl Group-Containing Drugs: A Review of 20 Years
Aathira Sujathan Nair, Ashutosh Kumar Singh, Astik Kumar, Sunil Kumar, Sunitha Sukumaran, Vishal Payyalot Koyiparambath, Leena K. Pappachen, T. M. Rangarajan, Hoon Kim, Bijo Mathew
Processes.2022; 10(10): 2054. CrossRef
Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, Nigel H. Greig
Pharmacological Research.2022; 186: 106550. CrossRef
An evaluation of drug lag for new drugs approved by the Indian regulator relative to the United States, European Union, and Japanese regulatory agencies
Mahanjit Konwar, Mitesh R. Maurya, Tushar B. Nishandar, Urmila M. Thatte, Nithya J. Gogtay
Perspectives in Clinical Research.2021; 12(3): 159. CrossRef
Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study
Eunsol Yang, Hyounggyoon Yoo, In-Jin Jang, Kyung-Sang Yu, SeungHwan Lee
Drug Design, Development and Therapy.2021; Volume 15: 651. CrossRef
Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis
Deep Dutta, Anshita Agarwal, Indira Maisnam, Rajiv Singla, Deepak Khandelwal, Meha Sharma
Endocrinology and Metabolism.2021; 36(2): 374. CrossRef
Structure–Activity Relationship Analysis of Cocrystallized Gliptin-like Pyrrolidine, Trifluorophenyl, and Pyrimidine-2,4-Dione Dipeptidyl Peptidase-4 Inhibitors
Katarina Tomovic, Budimir S. Ilic, Andrija Smelcerovic
Journal of Medicinal Chemistry.2021; 64(14): 9639. CrossRef
A review upon medicinal perspective and designing rationale of DPP-4 inhibitors
Shubham Kumar, Anu Mittal, Amit Mittal
Bioorganic & Medicinal Chemistry.2021; 46: 116354. CrossRef
Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial
Thananda Trakarnvanich, Bancha Satirapoj, Swangjit Suraamornkul, Thanit Chirananthavat, Anoma Sanpatchayapong, Torpong Claimon, Eusebio Chiefari
Journal of Diabetes Research.2021; 2021: 1. CrossRef
Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system
Hojin Oh, Hai Duc Nguyen, In Mo Yoon, Byung-Ryong Ahn, Min-Sun Kim
Scientific Reports.2021;[Epub] CrossRef
Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control
Seon Mee Kang, Jeong Hyun Park
Clinical Medicine Insights: Endocrinology and Diabetes.2021;[Epub] CrossRef
The vasodilatory effect of gemigliptin via activation of voltage-dependent K+ channels and SERCA pumps in aortic smooth muscle
Hee Seok Jung, Mi Seon Seo, Jin Ryeol An, Minji Kang, Ryeon Heo, Hongliang Li, Won-Kyo Jung, Il-Whan Choi, Eun-Hee Cho, Hongzoo Park, Young Min Bae, Won Sun Park
European Journal of Pharmacology.2020; 882: 173243. CrossRef
Development and Validation of a Rapid and Sensitive Method for the Simultaneous Estimation of Gemigliptin and Teneligliptin in Bulk and Dosage Forms by Using Liquid Chromatography-tandem Mass Spectrometry
Amrish Chandra, Ramji Rathod, Faraat Ali, Anuj Prakash, Robin Kumar, Gyanendra Nath Singh
Current Pharmaceutical Analysis.2020; 16(8): 1104. CrossRef
Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury
Elliot J. Glotfelty, Thomas E. Delgado, Luis B. Tovar-y-Romo, Yu Luo, Barry J. Hoffer, Lars Olson, Tobias E. Karlsson, Mark P. Mattson, Brandon K. Harvey, David Tweedie, Yazhou Li, Nigel H. Greig
ACS Pharmacology & Translational Science.2019; 2(2): 66. CrossRef
Mechanisms and pathways of anti‐inflammatory activity of DPP‐4 inhibitors in cardiovascular and renal protection
Katarina Tomovic, Jelena Lazarevic, Gordana Kocic, Marina Deljanin‐Ilic, Marko Anderluh, Andrija Smelcerovic
Medicinal Research Reviews.2019; 39(1): 404. CrossRef
Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study
Yoo-Ri Chung, Kyoung Hwa Ha, Hyeon Chang Kim, Sang Jun Park, Kihwang Lee, Dae Jung Kim
Diabetes & Metabolism Journal.2019; 43(5): 640. CrossRef
Effect of gemigliptin on cardiac ischemia/reperfusion and spontaneous hypertensive rat models
Dae-Hwan Nam, Jinsook Park, Sun-Hyun Park, Ki-Suk Kim, Eun Bok Baek
The Korean Journal of Physiology & Pharmacology.2019; 23(5): 329. CrossRef
Clinical Use of DPP-4 Inhibitors
Baptist Gallwitz
Frontiers in Endocrinology.2019;[Epub] CrossRef
Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report
Hae Jin Kim, Young Sik Kim, Chang Beom Lee, Moon-Gi Choi, Hyuk-Jae Chang, Soo Kyoung Kim, Jae Myung Yu, Tae Ho Kim, Ji Hyun Lee, Kyu Jeung Ahn, Kyoungmin Kim, Kwan Woo Lee
Diabetes Therapy.2019; 10(4): 1271. CrossRef
Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus
Jaehyun Bae, Youjin Kim, Yongin Cho, Minyoung Lee, Ji-Yeon Lee, Yong-ho Lee, Byung-Wan Lee, Bong-Soo Cha, Dong Jin Joo, Kyu Ha Huh, Myoung Soo Kim, Yu Seun Kim, Eun Seok Kang
Transplantation Proceedings.2019; 51(10): 3444. CrossRef
Protective effects of gemigliptin against type II collagen degradation in human chondrocytes
Momin Mohetaer, Guoqing Li, Yang Wang, Li Cao
Biomedicine & Pharmacotherapy.2018; 104: 590. CrossRef
Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers
Ignacio Conde-Carmona, Sandra García-Medina, Juan M. Jiménez-Vargas, Alberto Martínez-Muñoz, Sung-Hack Lee
Clinical Therapeutics.2018; 40(10): 1729. CrossRef
Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40‐week extension of the GUARD randomized study
Sang Youb Han, Sun Ae Yoon, Byoung Geun Han, Sung Gyun Kim, Young‐Il Jo, Kyung Hwan Jeong, Kook‐Hwan Oh, Hyeong Cheon Park, Sun‐Hee Park, Shin‐Wook Kang, Ki‐Ryang Na, Sun Woo Kang, Nam‐Ho Kim, Younghwan Jang, Bogyeong Kim, Seonghye Shin, Dae Ryong Cha
Diabetes, Obesity and Metabolism.2018; 20(2): 292. CrossRef
Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
Kyoung Hwa Ha, Bongseong Kim, Hae Sol Shin, Jinhee Lee, Hansol Choi, Hyeon Chang Kim, Dae Jung Kim
Korean Circulation Journal.2018; 48(5): 395. CrossRef
Gemigliptin: Newer promising gliptin for type 2 diabetes mellitus
Manish Gutch, Abhay Joshi, Sukriti Kumar, Avinash Agarwal, RajendraKumar Pahan, SyedMohd Razi
Indian Journal of Endocrinology and Metabolism.2017; 21(6): 898. CrossRef
Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice
Seung Hee Choi, Jaechan Leem, In-Kyu Lee
Mediators of Inflammation.2017; 2017: 1. CrossRef
Effects of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, on lipid metabolism and endotoxemia after a high‐fat meal in patients with type 2 diabetes
Chang Ho Ahn, Eun Ky Kim, Se Hee Min, Tae Jung Oh, Young Min Cho
Diabetes, Obesity and Metabolism.2017; 19(3): 457. CrossRef
Efficacy and safety of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24‐week, multicentre, randomized, double‐blind, placebo‐
Chang Ho Ahn, Kyung Ah Han, Jae Myung Yu, Joo Young Nam, Kyu Jeung Ahn, Tae Keun Oh, Hyoung Woo Lee, Dae Ho Lee, Jaetaek Kim, Choon Hee Chung, Tae Sun Park, Byung Joon Kim, Seok Won Park, Hyeong Kyu Park, Kwang Jae Lee, Sang‐Wook Kim, Jeong Hyun Park, Kwa
Diabetes, Obesity and Metabolism.2017; 19(5): 635. CrossRef

First
Prev
Page of 2
Next
Last

Search